Document:

EX-4.14

 Exhibit 4.14 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 EXECUTION
VERSION 
 SHAREHOLDERS AGREEMENT 

THIS SHAREHOLDERS AGREEMENT (this “Agreement”) is made and entered into as of November 7, 2018 by and among: 

 

	(1)	 VISEN Pharmaceuticals, a company established under the laws of Cayman Islands (the “Company”),

  

	(2)	 Ascendis Pharma Endocrinology Division A/S, a company established under the Laws of Denmark, Ascendis Pharma
Bone Diseases A/S, a company established under the Laws of Denmark, Ascendis Pharma Growth Disorders A/S, a company established under the Laws of Denmark and Ascendis Pharma A/S, a company organized under the laws of Denmark (collectively,
“Ascendis”), 

  

	(3)	 Vivo Plenilune IX Limited, a company established under the Laws of Cayman Islands (“Vivo
Capital”), 

  

	(4)	 Sofinnova Venture Partners IX, L.P., a limited partnership established under the Laws of the State of Delaware
(“Sofinnova,” together with Ascendis and Vivo Capital, each an “Investor”, and collectively the “Investors”), 

 

	(5)	 A private company limited by shares and a wholly owned subsidiary of the Company to be established under the
laws of Hong Kong, which will accede to this Agreement as a Party upon its establishment (the “HK Subsidiary”), and 

  

	(6)	 A limited liability company and a wholly owned subsidiary of the HK Subsidiary to be established under the laws
of the People’s Republic of China (excluding Hong Kong, Macao and Taiwan, the “PRC”), which will accede to this Agreement as a Party upon its establishment (the “WFOE”). 

The Company, the HK Subsidiary and the WFOE are referred to collectively herein as the “Group Companies”, and each, a “Group
Company”. Each of the forgoing parties is referred to herein individually as a “Party” and collectively as the “Parties”. 

RECITALS 

A.    The Company and the Investors have entered into a Series A Preferred Share Purchase Agreement dated as of the date
hereof (the “Share Purchase Agreement”), under which, among other things, the Company shall issue and allot certain number of series A preferred shares of the Company, par value US$0.0001 per share (the “Series A Preferred
Shares”) to the Investors, at the Closings. 
 B.    In connection with the consummation of the transactions
contemplated by the Share Purchase Agreement, the parties hereto desire to enter into this Agreement and the other Transaction Documents for the governance, management and operations of the Group Companies and for the rights and obligations among
the holders of Series A Preferred Shares and the Company. 

  
 1 

 C.    The Share Purchase Agreement provides that the execution and
delivery of this Agreement by the parties shall be a condition precedent to the consummation of the transactions contemplated under the Share Purchase Agreement. 

D.    Unless otherwise defined in this Agreement, capitalized terms used in this Agreement shall have the meanings set
forth in the Share Purchase Agreement. 
 NOW, THEREFORE, in consideration of the foregoing recitals, the mutual promises hereinafter set
forth, and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereby agree as follows: 

1.    INFORMATION RIGHTS; BOARD REPRESENTATION. 

1.1.    Information and Inspection Rights. 

(a)    Information Rights. The Company covenants and agrees that, commencing on the date of this Agreement, the
Company shall deliver to each holder of the Series A Preferred Shares holding no less than ten percent (10%) of the Company’s total issued and outstanding Series A Preferred Shares: 

(i)    within thirty (30) days after the end of each fiscal quarter, unaudited quarterly consolidated financial
statements and other documents reflecting the business activities and performance (including but not limited to tax filings and management reports) for such quarter and analysis of the Group Companies’ business operation; 

(ii)    within forty-five (45) days after the end of each fiscal year, unaudited annual consolidated financial
statements for such fiscal year and implementation of the budget for such fiscal year; and 
 (iii)    within four
(4) months after the end of each fiscal year, audited annual consolidated financial statements for such fiscal year, audited by the accounting firms reasonably acceptable to Ascendis and Vivo Capital (the “Major Investors”).

 Promptly upon the written request by any holder of Series A Preferred Shares representing no less than ten percent (10%) of the
Company’s total issued and outstanding Series A Preferred Shares, such other information as such holder of Series A Preferred Shares shall reasonably request from time to time, including, without limitation, an up-to-date capitalization table, the most recent version of the investment agreements, documents relating to subsequent financing and a copy of the official articles of association or other constitutional
documents of the Group Companies. In addition, the Company shall provide to Ascendis such information and financial statements of the Group Companies and provide access to personnel reasonably requested by Ascendis in order for Ascendis to timely
comply with applicable disclosure and financial and tax reporting requirements. The rights set forth above shall be collectively referred to as the “Information Rights”. 

All financial statements to be provided to such holder of Series A Preferred Shares pursuant to this Section 1.1(a)
shall be in English and shall include an income statement, a balance sheet, a cash flow statement for the relevant period as well as for the fiscal year to-date and shall be prepared in conformance with the
PRC Generally Accepted Accounting Principles (the “PRC GAAP”) with respect to the Group Companies in the PRC, or the International Financial Reporting Standards (the “IFRS”) with respect to the Company and the Group
Company outside of the PRC. 

  
 2 

 (b)    Inspection Rights. The Company further covenants and
agrees that, commencing on the date of this Agreement, for so long as Ascendis or Vivo Capital continues to hold Series A Preferred Shares or Ordinary Shares issued or issuable upon conversion thereof representing no less than ten percent (10%) of
the Company’s total outstanding share capital on fully-diluted and as-converted basis, each such Investor shall have (i) the right to inspect facilities, records and books of the Group Companies at
any time during regular working hours upon reasonable prior notice to the Company, (ii) the right to discuss the business, operations and conditions of the Group Companies with their respective directors, officers, employees, accountants, legal
counsel, financial advisors, and investment bankers, and (iii) the right to dispatch auditing personnel of its own or hire independent auditors to audit the books and records of the Group Companies as needed (the “Inspection
Rights”). Such auditing personnel or independent auditors shall have access to all financial statements, financial records, original receipts and other documents of the Group Companies. Such audit shall not be conducted more than two
(2) times per year. The Company shall, and shall cause the Group Companies to provide necessary assistance for such audit. The Investor that hires an independent auditor shall bear the cost of such auditor. 

1.2.    Board of Directors and Observers. The Amended and Restated Memorandum and Articles of Association of the
Company (the “Restated Articles”) shall provide that the board of directors of the Company (the “Board”) shall consist of five (5) members, which number of members shall not be changed except pursuant to an
amendment to the Restated Articles. Effective from the date hereof, 
 (a)    Ascendis shall be entitled to appoint and
remove one (1) director, who shall initially be Jan Moller Mikkelsen (the “Ascendis Director”), 

(b)    Vivo Capital shall be entitled to appoint and remove two (2) directors, who shall initially be Shan FU and
Dandan DONG, (each, a “Vivo Capital Director,” and collectively, the “Vivo Capital Directors,” together with the Ascendis Director, the “Series A Directors”) and shall be entitled to appoint one
(1) such member to any committee of the Board, 
 (c)    the person then serving as the Chief Executive Officer of
the Company shall be appointed as a director of the Company, and 
 (d)    one (1) independent person who is not
employed by any Group Company, who is not Affiliated with any Group Company or any Investor and who is mutually acceptable to the Major Investors. 

Vivo Capital shall also be entitled to appoint one (1) observer (the “Observer”) to attend all meetings of the Board in
a non-voting, observer capacity, and to receive concurrently with the members of the Board all notices of Board meetings (and copies of materials distributed at or in connection with Board meetings). A meeting
of directors is duly constituted for all purposes if at the commencement of the meeting there are present in person or by alternate such number of directors not less than a majority of the directors of the Company, which directors in each case shall
include each of the Series A Directors, provided, however, that if a requisite quorum is not achieved based on the failure to attend such meeting by any Series A Director, then the quorum at such rescheduled meeting shall be a majority
of the Directors then in office. The Company shall reimburse the directors and the Observer for all reasonable out-of-pocket expenses incurred in connection with
attending any meetings of the Board and any committee thereof. 

  
 3 

 1.3.    Board of Directors of Subsidiaries. The size and
composition of the board of directors of any subsidiary of the Company, whether now in existence or formed in the future (the “Subsidiaries”), which is wholly owned directly or indirectly by the Company, shall mirror the Board. 

1.4.    Voting Agreement. Each Party agrees that it shall vote all of its Shares (or give shareholders’
consent) in such manner that gives effect to the provisions of this Agreement, including without limitation to cause the Board to be constituted in accordance with Section 1.2. 

1.5.    Termination. The provisions set forth under this Section 1 shall terminate upon
the earlier to occur of (i) a firm-commitment underwritten initial public offering by the Company of its Ordinary Shares or a reverse merger of the Company with a listed company, on a reputable securities exchange in the United States, Hong
Kong or PRC (excluding the National Equities Exchange And Quotations of the PRC), or any other jurisdiction, including without limitations, the New York Stock Exchange or the Nasdaq Global Market in the United States and the Main Board of the Hong
Kong Stock Exchange, with a per share price of at least US$[***] (subject to adjustments for share dividends, splits, combinations, recapitalization and similar events) and net proceeds to the Company of at least US$[***] (the “Qualified
Initial Public Offering”), and (ii) the closing of a Liquidation Event (as defined in the Restated Articles). 

2.    REGISTRATION RIGHTS. 

2.1.    Applicability of Rights. The Holders (as defined below) shall be entitled to the following rights with
respect to any proposed public offering of the Company’s Ordinary Shares in the United States and shall be entitled to reasonably equivalent or analogous rights with respect to any other offering of the Company’s securities in the Hong
Kong SAR or any other jurisdiction in which the Company undertakes to publicly offer or list such securities for trading on a recognized securities exchange. 

2.2.    Definitions. For purposes of this Section 2: 

(a)    Registration. The terms “register,” “registered,” and
“registration” refer to a registration effected by filing a registration statement which is in a form which complies with, and is declared effective by the SEC (as defined below) in accordance with, the Securities Act of 1933, as
amended to date (the “Securities Act”). 
 (b)    Registrable Securities. The term
“Registrable Securities” means: (1) any Ordinary Shares of the Company issued or issuable pursuant to conversion of any issued and outstanding shares of Series A Preferred Shares, excluding any Ordinary Shares issued upon
conversion of the Series A Preferred Shares pursuant to Article 36A of the Company’s Restated Articles (Special Mandatory Conversion), (2) any Ordinary Shares issued (or issuable upon the conversion or exercise of any warrant, right or other
security which is issued) as a dividend or other distribution with respect to, or in exchange for or in replacement of, any Series A Preferred Shares described in clause (1) of this subsection (b), and (3) any

  
 4 

 
other Ordinary Shares of the Company owned or hereafter acquired by the Investors. Notwithstanding the foregoing, “Registrable Securities” shall exclude any Registrable
Securities sold by a person in a transaction in which rights under this Section 2 are not validly assigned in accordance with this Agreement, and any Registrable Securities which are sold in a registered public offering
under the Securities Act or analogous statute of another jurisdiction, or sold pursuant to Rule 144 promulgated under the Securities Act or analogous rule of another jurisdiction. 

(c)    Registrable Securities Then Outstanding. The number of shares of “Registrable Securities then
Outstanding” shall mean the number of Ordinary Shares of the Company that are Registrable Securities and are then issued and outstanding, issuable upon conversion of Series A Preferred Shares then issued and outstanding, or issuable upon
conversion or exercise of any warrant, right or other security then outstanding. 
 (d)    Holder. For purposes
of this Section 2, the term “Holder” means any person owning or having the rights to acquire Registrable Securities or any permitted assignee of record of such Registrable Securities to whom rights under
this Section 2 have been duly assigned in accordance with this Agreement. 
 (e)    Form F-3. The term “Form F-3” means such respective form under the Securities Act or any successor registration form under the Securities Act subsequently
adopted by the SEC which permits inclusion or incorporation of substantial information by reference to other documents filed by the Company with the SEC. 

(f)    SEC. The term “SEC” or “Commission” means the U.S. Securities and
Exchange Commission. 
 (g)    Registration Expenses. The term “Registration Expenses” shall
mean all expenses incurred by the Company in complying with Sections 2.3, 2.4 and 2.5 hereof, including, without limitation, all registration and filing fees, printing expenses, fees, and disbursements of
counsel for the Company, reasonable fees and disbursements, not to exceed US$30,000, of one special counsel for all the Holders, “blue sky” fees and expenses, fees and expenses charged by share registrar and depository agent and the
expense of any special audits incident to or required by any such registration (but excluding the compensation of regular employees of the Company which shall be paid in any event by the Company).  

(h)    Selling Expenses. The term “Selling Expenses” shall mean all underwriting discounts and
selling commissions applicable to the sale of Registrable Securities pursuant to Sections 2.3, 2.4 and 2.5 hereof. 

(i)    Exchange Act. The term “Exchange Act” shall mean the Securities Exchange Act of 1934, as
amended, and any successor statute. 

  
 5 

 2.3.    Demand Registration. 

(a)    Request by Holders. If the Company shall, at any time after the earlier of (i) three (3) years after
the Initial Closing or (ii) six (6) months following the taking effect of a registration statement for the initial underwritten public offering of the securities of the Company (the “IPO”), receive a written request from the
Holders of at least [***] percent ([***]%) of the Registrable Securities then Outstanding that the Company file a registration statement under the Securities Act on any internationally recognized exchange that is acceptable to such requesting
Holders pursuant to this Section 2.3 covering the registration of the Registrable Securities then Outstanding subject to a minimum offering size of US$15,000,000, then the Company shall, within ten (10) Business Days
of the receipt of such written request, give written notice of such request (the “Request Notice”) to all Holders, and use its best efforts to effect, as soon as practicable, the registration under the Securities Act of all
Registrable Securities that the Holders request to be registered and included in such registration by written notice given by such Holders to the Company within twenty (20) days after receipt of the Request Notice, subject only to the
limitations of this Section 2.3; provided that the Company shall not be obligated to effect any such registration if the Company has, within the six (6) month period preceding the date of such request, already
effected a registration under the Securities Act pursuant to this Section 2.3 or Section 2.5 or in which the Holders had an opportunity to participate pursuant to the provisions of
Section 2.4, other than a registration from which the Registrable Securities of the Holders have been excluded (with respect to all or any portion of the Registrable Securities the Holders requested be included in such
registration) pursuant to the provisions of Section 2.4(a). The Company shall be obligated to effect no more than two (2) Registration pursuant to this Section 2.3. A registration shall not be
counted as “effected” for purposes of this Section 2.3(a) until such time as the applicable registration statement has been declared effective by the SEC, unless the Initiating Holders (as defined below) withdraw
their request for such registration, elect not to pay the registration expenses therefor, and forfeit their right to one demand registration statement pursuant to Section 2.6, in which case such withdrawn registration
statement shall be counted as “effected” for purposes of this Section 2.3(a). For purposes of this Agreement, reference to registration of securities under the Securities Act and the Exchange Act shall be deemed
to mean the equivalent registration in a jurisdiction other than the United States as designated by such Holders, it being understood and agreed that in each such case all references in this Agreement to the Securities Act, the Exchange Act and
rules, forms of registration statements and registration of securities thereunder, U.S. law and the SEC, shall be deemed to refer, to the equivalent statutes, rules, forms of registration statements, registration of securities and laws of and
equivalent government authority in the applicable non-U.S. jurisdiction. 

(b)    Underwriting. If the Holders initiating the registration request under this
Section 2.3 (the “Initiating Holders”) intend to distribute the Registrable Securities covered by their request by means of an underwriting, then they shall so advise the Company as a part of their request
made pursuant to this Section 2.3 and the Company shall include such information in the Request Notice. In such event, the right of any Holder to include its Registrable Securities in such registration shall be conditioned
upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting (unless otherwise mutually agreed by a majority in interest of the Initiating Holders and such Holder) to
the extent provided herein. All Holders proposing to distribute their securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter or underwriters selected for such underwriting by
the Holders of a majority of the Registrable Securities being registered and reasonably acceptable to the Company. Notwithstanding any other provision of this Section 2.3, if the underwriter(s) advise(s) the Company in
writing that marketing factors require a limitation of the number of securities to be underwritten, then the Company shall so advise all Holders of Registrable Securities which would otherwise be registered and underwritten pursuant hereto, and the
number of Registrable Securities that may be included in the underwriting shall be reduced as required by the underwriter(s) and allocated among the Holders of Registrable Securities on a pro rata basis according to the number of Registrable
Securities then 

  
 6 

 
Outstanding held by each Holder requesting registration (including the Initiating Holders); provided, however, that the number of shares of Registrable Securities to be included in
such underwriting and registration shall not be reduced unless all other securities are first entirely excluded from the underwriting and registration including, without limitation, all shares that are not Registrable Securities and are held by any
other person, including, without limitation, any person who is an employee, officer or director of the Company or any subsidiary of the Company; provided further, that at least twenty-five percent (25%) of Registrable Securities
requested by the Holders to be included in such underwriting and registration shall be so included. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the
underwriter(s), delivered at least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration.

 2.4.    Piggyback Registrations. 

(a)    The Company shall notify all Holders of Registrable Securities in writing at least thirty (30) days prior to
filing any registration statement under the Securities Act for purposes of effecting a public offering of securities of the Company (including, but not limited to, registration statements relating to secondary offerings of securities of the Company,
but excluding registration statements relating to any employee benefit plan or a corporate reorganization), and shall afford each such Holder an opportunity to include in such registration statement all or any part of the Registrable Securities then
held by such Holder. Each Holder desiring to include in any such registration statement all or any part of the Registrable Securities held by it shall within twenty (20) days after receipt of the above-described notice from the Company, so
notify the Company in writing, and in such notice shall inform the Company of the number of Registrable Securities such Holder wishes to include in such registration statement. If a Holder decides not to include all of its Registrable Securities in
any registration statement thereafter filed by the Company, such Holder shall nevertheless continue to have the right to include any Registrable Securities in any subsequent registration statement or registration statements as may be filed by the
Company with respect to offerings of its securities, all upon the terms and conditions set forth herein. No Holder of Registrable Securities shall be granted piggyback registration rights superior to those of the Holders of the Series A Preferred
Shares without the consent in writing of the Holders of at least fifty percent (50%) of the Registrable Securities. 

(b)    Underwriting. If a registration statement under which the Company gives notice under this
Section 2.4 is for an underwritten offering, then the Company shall so advise the Holders of Registrable Securities. In such event, the right of any such Holder’s Registrable Securities to be included in a registration
pursuant to this Section 2.4 shall be conditioned upon such Holder’s participation in such underwriting and the inclusion of such Holder’s Registrable Securities in the underwriting to the extent provided herein.
All Holders proposing to distribute their Registrable Securities through such underwriting shall enter into an underwriting agreement in customary form with the managing underwriter or underwriters selected for such underwriting. Notwithstanding any
other provision of this Agreement but subject to Section 2.13, if the managing underwriter(s) determine(s) in good faith that marketing factors require a limitation of the number of shares to be underwritten, then the
managing underwriter(s) may exclude shares from the registration and the underwriting, and the number of shares that may be included in the registration and the underwriting shall be allocated, first, to the Company, second, to each of
the Holders requesting inclusion of their 

  
 7 

 
Registrable Securities in such registration statement on a pro rata basis based on the total number of shares of Registrable Securities then held by each such Holder, and third, to holders
of other securities of the Company; provided, however, that the right of the underwriter(s) to exclude shares (including Registrable Securities) from the registration and underwriting as described above shall be restricted so that
(i) the number of Registrable Securities included in any such registration is not reduced below twenty percent (20%) of the aggregate number of shares of Registrable Securities for which inclusion has been requested; and (ii) all shares
that are not Registrable Securities and are held by any other person, including, without limitation, any person who is an employee, officer or director of the Company (or any subsidiary of the Company) shall first be excluded from such registration
and underwriting before any Registrable Securities are so excluded. If any Holder disapproves of the terms of any such underwriting, such Holder may elect to withdraw therefrom by written notice to the Company and the underwriter(s), delivered at
least ten (10) business days prior to the effective date of the registration statement. Any Registrable Securities excluded or withdrawn from such underwriting shall be excluded and withdrawn from the registration. 

(c)    Not Demand Registration. Registration pursuant to this Section 2.4 shall not be
deemed to be a demand registration as described in Section 2.3 above. There shall be no limit on the number of times the Holders may request registration of Registrable Securities under this
Section 2.4. 
 2.5.    Form F-3. If at any
time when it is eligible to use a Form F-3 registration statement the Company shall receive from the Holders of at least thirty percent (30%) of the Registrable Securities then Outstanding a written request or
requests that the Company effect a registration on Form F-3 and any related qualification or compliance with respect to all or a part of the Registrable Securities owned by such Holder or Holders, then the
Company will: 
 (a)    Notice. Promptly give written notice of the proposed registration and the Holder’s
or Holders’ request therefor, and any related qualification or compliance, to all other Holders of Registrable Securities; and 

(b)    Registration. As soon as practicable, effect such registration and all such qualifications and compliances
as may be so requested and as would permit or facilitate the sale and distribution of all or such portion of such Holders or Holders’ Registrable Securities as are specified in such request, together with all or such portion of the Registrable
Securities of any other Holder or Holders joining in such request as are specified in a written request given within twenty (20) days after the Company provides the notice contemplated by Section 2.5(a);
provided, however, that the Company shall not be obligated to effect any such registration, qualification or compliance pursuant to this Section 2.5: 

(i)    if the Holders, together with the holders of any other securities of the Company entitled to inclusion in such
registration, propose to sell Registrable Securities and such other securities (if any) at an aggregate price to the public of less than US$5,000,000; 

  
 8 

 (ii)    if the Company shall furnish to the Holders a certificate
signed by the President or Chief Executive Officer of the Company stating that in the good faith judgment of the Board, it would be materially detrimental to the Company and its shareholders for such Form F-3
registration to be effected at such time, in which event the Company shall have the right to defer the filing of the Form F-3 registration statement no more than once during any twelve (12) month period
for a period of not more than sixty (60) days after receipt of the request of the Holder or Holders under this Section 2.5; provided that the Company shall not register any of its other shares during such sixty
(60) day period; A registration right under this Section 2.5 shall not be deemed to have been exercised until such deferred registration shall have been effected; 

(iii)    if the Company has, within the twelve (12) month period preceding the date of such request, already
effected one (1) registration on Form F-3; 
 (iv)    if the Company has,
within the twelve (12) month period preceding the date of such request, already effected two (2) registrations under the Securities Act other than a registration from which the Registrable Securities of Holders have been excluded (with
respect to all or any portion of the Registrable Securities the Holders requested be included in such registration) pursuant to the provisions of Sections 2.3(b) and 2.4 (a); or 

(v)    in any particular jurisdiction in which the Company would be required to qualify to do business or to execute a
general consent to service of process in effecting such registration, qualification or compliance. 
 Subject to the foregoing, the Company shall file a
Form F-3 registration statement covering the Registrable Securities and other securities so requested to be registered as soon as practicable after receipt of the request or requests of the Holders. 

(c)    Not Demand Registration. Form F-3 registrations shall not be deemed
to be demand registrations as described in Section 2.3 above. Except as otherwise provided herein, there shall be no limit on the number of times the Holders may request registration of Registrable Securities under this
Section 2.5. 
 2.6.    Expenses. All Registration Expenses incurred in connection with
any registration pursuant to Sections 2.3, 2.4 or 2.5 (but excluding Selling Expenses) shall be borne by the Company. Each Holder participating in a registration pursuant to Sections 2.3, 2.4 or 2.5 shall
bear such Holder’s proportionate share (based on the total number of shares sold in such registration other than for the account of the Company) of all Selling Expenses or other amounts payable to underwriter(s) or brokers, in connection with
such offering by the Holders. Notwithstanding the foregoing, the Company shall not be required to pay for any expenses of any registration proceeding begun pursuant to Section 2.3 if the registration request is subsequently
withdrawn at the request of the Holders of a majority of the Registrable Securities to be registered, unless the Holders of a majority of the Registrable Securities then Outstanding agree that such registration constitutes the use by the Holders of
one (1) demand registration pursuant to Section 2.3; provided further, however, that if at the time of such withdrawal, the Holders have learned of a material adverse change in the condition,
business, or prospects of the Company not known to the Holders at the time of their request for such registration and have withdrawn their request for registration with reasonable promptness after learning of such material adverse change, then the
Holders shall not be required to pay any of such expenses and such registration shall not constitute the use of a demand registration pursuant to Section 2.3. 

  
 9 

 2.7.    Obligations of the Company. Whenever required to effect
the registration of any Registrable Securities under this Agreement the Company shall, as expeditiously as reasonably possible: 

(a)    Registration Statement. Prepare and file with the SEC a registration statement with respect to such
Registrable Securities and use its best efforts to cause such registration statement to become effective, and, upon the request of the Holders of a majority of the Registrable Securities registered thereunder, keep such registration statement
effective for a period of up to ninety (90) days or, in the case of Registrable Securities registered under Form F-3 in accordance with Rule 415 under the Securities Act or a successor rule, until the
distribution contemplated in the registration statement has been completed; provided, however, that (i) such ninety (90) day period shall be extended for a period of time equal to the period any Holder refrains from selling
any securities included in such registration at the request of the underwriter(s), and (ii) in the case of any registration of Registrable Securities on Form F-3 which are intended to be offered on a
continuous or delayed basis, such ninety (90) day period shall be extended, if necessary, to keep the registration statement effective until all such Registrable Securities are sold. 

(b)    Amendments and Supplements. Prepare and file with the SEC such amendments and supplements to such
registration statement and the prospectus used in connection with such registration statement as may be necessary to comply with the provisions of the Securities Act with respect to the disposition of all securities covered by such registration
statement. 
 (c)    Prospectuses. Furnish to the Holders such number of copies of a prospectus, including a
preliminary prospectus, in conformity with the requirements of the Securities Act, and such other documents as they may reasonably request in order to facilitate the disposition of the Registrable Securities owned by them that are included in such
registration. 
 (d)    Blue Sky. Use its best efforts to register and qualify the securities covered by such
registration statement under such other securities or “blue sky” laws of such jurisdictions as shall be reasonably requested by the Holders, provided that the Company shall not be required in connection therewith or as a condition thereto
to qualify to do business or to file a general consent to service of process in any such states or jurisdictions, unless the Company is already subject to service in such jurisdiction and except as may be required by the Securities Act. 

(e)    Underwriting. In the event of any underwritten public offering, enter into and perform its obligations
under an underwriting agreement in usual and customary form, with the managing underwriter(s) of such offering. Each Holder participating in such underwriting shall also enter into and perform its obligations under such an agreement. 

(f)    Notification. Notify each Holder of Registrable Securities covered by such registration statement at any
time when a prospectus relating thereto is required to be delivered under the Securities Act of (i) the issuance of any stop order by the SEC in respect of such registration statement, or (ii) the happening of any event as a result of
which the prospectus included in such registration statement, as then in effect, includes an untrue statement of a material fact or omits to state a material fact required to be stated therein or necessary to make the statements therein not
misleading in the light of the circumstances then existing. 

  
 10 

 (g)    Opinion and Comfort Letter. Furnish, at the request of
any Holder requesting registration of Registrable Securities, on the date that such Registrable Securities are delivered to the underwriter(s) for sale, if such securities are being sold through underwriters, or, if such securities are not being
sold through underwriters, on the date that the registration statement with respect to such securities becomes effective, (i) an opinion, dated as of such date, of the counsel representing the Company for the purposes of such registration, in
form and substance as is customarily given to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the Holders requesting registration, addressed to the underwriters, if any, and to the Holders
requesting registration of Registrable Securities and (ii) letters dated as of (x) the effective date of the registration statement covering such Registrable Securities and (y) the closing date of the offering, from the independent
certified public accountants of the Company, in form and substance as is customarily given by independent certified public accountants to underwriters in an underwritten public offering and reasonably satisfactory to a majority in interest of the
Holders requesting registration, addressed to the underwriters, if any, and to the Holders requesting registration of Registrable Securities. 

2.8.    Furnish Information. It shall be a condition precedent to the obligations of the Company to take any action
pursuant to Sections 2.3, 2.4 or 2.5 that the selling Holders shall furnish to the Company such information regarding themselves, the Registrable Securities held by them and the intended method of disposition of such securities
as shall be required to timely effect the Registration of their Registrable Securities. 

2.9.    Indemnification. In the event any Registrable Securities are included in a registration statement under
Sections 2.3, 2.4 or 2.5: 
 (a)    By the Company. To the extent permitted by law and the
Restated Articles, the Company will indemnify and hold harmless each Holder, its partners, officers, directors, legal counsel, any underwriter (as defined in the Securities Act) for such Holder and each person, if any, who controls such Holder or
underwriter within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages, or liabilities (joint or several) to which they may become subject under the Securities Act, the Exchange Act, or other United States
federal or state law, insofar as such losses, claims, damages, or liabilities (or actions in respect thereof) arise out of or are based upon any of the following statements, omissions or violations (collectively a “Violation”): 

(i)    any untrue statement or alleged untrue statement of a material fact contained in such registration statement,
including any preliminary prospectus or final prospectus contained therein or any amendments or supplements thereto; 

(ii)    the omission or alleged omission to state therein a material fact required to be stated therein, or necessary to
make the statements therein not misleading; or 
 (iii)    any violation or alleged violation by the Company of the
Securities Act, the Exchange Act, any United States federal or state securities law, or any rule or regulation promulgated under the Securities Act, the Exchange Act, or any United States federal or state securities law in connection with the
offering covered by such registration statement; 

  
 11 

 and the Company will reimburse each such Holder, its partner, officer, director, legal counsel, underwriter
or controlling person for any legal or other expenses reasonably incurred by them, as such expenses are incurred, in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that
the indemnity agreement contained in this subsection 2.9(a) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Company (which consent shall not
be unreasonably withheld), nor shall the Company be liable in any such case for any such loss, claim, damage, liability or action to the extent that it arises out of or is based upon a Violation which occurs in reliance upon and in conformity with
written information furnished expressly for use in connection with such registration by such Holder, partner, officer, director, legal counsel, underwriter or controlling person of such Holder. 

(b)    By Selling Holders. To the extent permitted by law, each selling Holder will, if Registrable Securities
held by Holder are included in the securities as to which such registration qualifications or compliance is being effected, indemnify and hold harmless the Company, each of its directors, each of its officers who has signed the registration
statement, each person, if any, who controls the Company within the meaning of the Securities Act, any underwriter and any other Holder selling securities under such registration statement or any of such other Holder’s partners, directors,
officers, legal counsel or any person who controls such Holder within the meaning of the Securities Act or the Exchange Act, against any losses, claims, damages or liabilities (joint or several) to which the Company or any such director, officer,
legal counsel, controlling person, underwriter or other such Holder, partner or director, officer or controlling person of such other Holder may become subject under the Securities Act, the Exchange Act or other United States federal or state law,
insofar as such losses, claims, damages or liabilities (or actions in respect thereto) arise out of or are based upon any Violation, in each case to the extent (and only to the extent) that such Violation occurs in reliance upon and in conformity
with written information furnished by such Holder expressly for use in connection with such registration; and each such Holder will reimburse any legal or other expenses reasonably incurred by the Company or any such director, officer, controlling
person, underwriter or other Holder, partner, officer, director or controlling person of such other Holder in connection with investigating or defending any such loss, claim, damage, liability or action; provided, however, that the
indemnity agreement contained in this subsection 2.9(b) shall not apply to amounts paid in settlement of any such loss, claim, damage, liability or action if such settlement is effected without the consent of the Holder, which consent shall not be
unreasonably withheld; and provided, further, that in no event shall any indemnity under this Section 2.9(b) together with any amount contributed pursuant to Section 2.9(d) below
exceed the net proceeds (net of any Selling Expenses paid by such Holder) received by such Holder in the registered offering out of which the applicable Violation arises, except in the case of willful misconduct or fraud by such Holder. 

(c)    Notice. Promptly after receipt by an indemnified party under this Section 2.9 of
notice of the commencement of any action (including any governmental action), such indemnified party will, if a claim in respect thereof is to be made against any indemnifying party under this Section 2.9, deliver to the
indemnifying party a written notice of the commencement thereof and the indemnifying party shall have the right to participate in, and, to the extent the indemnifying party so desires, jointly with any other indemnifying party similarly noticed, to
assume the defense thereof with counsel mutually satisfactory to the parties; provided, however, that an indemnified party shall have the right to retain its own counsel, with the fees and expenses to be paid by the indemnifying party,
if representation of such indemnified party by the counsel retained by the indemnifying party would be inappropriate due to actual or potential conflict of interests between such indemnified party and any other party represented by such counsel in
such proceeding. The failure to deliver written notice to the indemnifying party within a reasonable time of the commencement of any such action shall relieve such indemnifying party of liability to the indemnified party under this
Section 2.9 to the extent the indemnifying party is prejudiced as a result thereof, but the omission to so deliver written notice to the indemnifying party will not relieve it of any liability that it may have to any
indemnified party otherwise than under this Section 2.9. 
  

  
 12 

 (d)    Contribution. In order to provide for just and equitable
contribution to joint liability under the Securities Act in any case in which either (i) any indemnified party makes a claim for indemnification pursuant to this Section 2.9 but it is judicially determined (by the
entry of a final judgment or decree by a court of competent jurisdiction and the expiration of time to appeal or the denial of the last right of appeal) that such indemnification may not be enforced in such case notwithstanding the fact that this
Section 2.9 provides for indemnification in such case, or (ii) contribution under the Securities Act may be required on the part of any indemnified party in circumstances for which indemnification is provided under
this Section 2.9; then, and in each such case, the indemnified party and the indemnifying party will contribute to the aggregate losses, claims, damages or liabilities to which they may be subject (after contribution from
others) in such proportion so that a Holder (together with its related persons) is responsible for the portion represented by the percentage that the public offering price of its Registrable Securities offered by and sold under the registration
statement bears to the public offering price of all securities offered by and sold under such registration statement, and the Company and other selling Holders are responsible for the remaining portion. The relative fault of the indemnifying party
and of the indemnified party shall be determined by a court of law by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission to state a material fact relates to information supplied by the
indemnifying party or by the indemnified party and the parties’ relative intent, knowledge, access to information and opportunity to correct or prevent such statement or omission; provided, however, that, in any such case:
(A) no Holder will be required to contribute any amount in excess of the net proceeds to such Holder from the sale of all such Registrable Securities offered and sold by such Holder pursuant to such registration statement; and (B) no
person or entity guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of the Securities Act) will be entitled to contribution from any person or entity who was not guilty of such fraudulent
misrepresentation. 
 (e)    Survival; Consents to Judgments and Settlements. The obligations of the Company and
Holders under this Section 2.9 shall survive until the fifth (5th) anniversary of the completion of any offering of Registrable Securities in a registration statement, regardless of the expiration of any statutes of
limitation or extensions of such statutes. No indemnifying party, in the defense of any such claim or litigation, shall, except with the consent of each indemnified party, consent to entry of any judgment or enter into any settlement which does not
include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect to such claim or litigation. 

2.10.    No Registration Rights to Third Parties. Without the prior written consent of the holders of at least
sixty percent (60%) of the Series A Preferred Shares then outstanding, the Company covenants and agrees that it shall not grant, or cause or permit to be created, for the benefit of any person or entity any registration rights of any kind (whether
similar to the demand, “piggyback” or Form F-3 registration rights described in this Section 2, or otherwise) relating to any securities of the Company which are senior to,
or on a parity with, those granted to the Holders of Registrable Securities. 

  
 13 

 2.11.    Rule 144 Reporting. With a view to making available to
the Holders the benefits of certain rules and regulations of the SEC which may at any time permit the sale of the Registrable Securities to the public without registration or pursuant to a registration on Form
F-3, after such time as a public market exists for the Ordinary Shares, the Company agrees to: 

(a)    Make and keep public information available, as those terms are understood and defined in Rule 144 under the
Securities Act, at all times after the effective date of the first registration under the Securities Act filed by the Company for an offering of its securities to the general public; 

(b)    File with the SEC in a timely manner all reports and other documents required of the Company under the Securities
Act and the Exchange Act (at any time after it has become subject to such reporting requirements); and 
 (c)    So
long as a Holder owns any Registrable Securities, to furnish to such Holder forthwith upon request (i) a written statement by the Company as to its compliance with the reporting requirements of Rule 144 (at any time after ninety (90) days
after the effective date of the Company’s initial public offering), the Securities Act and the Exchange Act (at any time after it has become subject to such reporting requirements), or its qualification as a registrant whose securities may be
resold pursuant to Form F-3 (at any time after it so qualifies), (ii) a copy of the most recent annual or quarterly report of the Company, and (iii) such other reports and documents of the Company as a
Holder may reasonably request in availing itself of any rule or regulation of the SEC that permits the selling of any such securities without registration or pursuant to Form F-3. 

2.12.    Market Stand-Off. Each party agrees that, so long as it holds any
voting securities of the Company, upon request by the Company or the underwriters managing the initial public offering of the Company’s securities, it will not sell or otherwise transfer or dispose of any securities of the Company held
immediately before the effective date of the registration statement for such offering (other than those permitted to be included in the registration and other transfers to Affiliates permitted by law) without the prior written consent of the
Company or such underwriters, as the case may be, for a period of time specified by the representative of the underwriters not to exceed 180 days from the effective date of the registration statement covering such initial public offering or the
pricing date of such offering as may be requested by the underwriters. The Company shall use commercially reasonable efforts to take all steps to shorten such lock-up period. The foregoing provision of this
Section 2.12 shall not apply to the sale of any securities of the Company to an underwriter pursuant to any underwriting agreement, and shall only be applicable to the Holders if all officers and directors of the Group
Companies and all shareholders owning more than five percent (5%) of the Company’s outstanding Ordinary Shares (on an as-converted basis) are subject to the same restrictions, and if the Company or any
underwriter releases any other shareholder from his, her or its sale restrictions so undertaken, then each Holder shall be notified prior to such release and shall itself be simultaneously released to the same proportional extent. The Company shall
require all future acquirers of the Company’s securities to execute prior to a Qualified Initial Public Offering a market stand-off agreement containing substantially similar provisions as those contained
in this Section 2.12. 

  
 14 

 2.13.    Termination. The registration rights in this
Section 2 shall terminate upon the earliest to occur of (i) the closing of a Liquidation Event; (ii) such time as Rule 144 or another similar exemption under the Securities Act or other applicable securities laws
is available for the sale of all of such Holder’s shares without registration; and (iii) the third anniversary of the Qualified Initial Public Offering. 

3.    RIGHT OF PARTICIPATION. 

3.1.    General. Each holder of Series A Preferred Shares, including each holder of Series A Preferred Shares to
which rights under this Section 3 have been duly assigned in accordance with Section 5 (hereinafter referred to as a “Participation Rights Holder”), shall have the preemptive right
to purchase such Participation Rights Holder’s Pro Rata Share (as defined below), of all (or any part) of any New Securities (as defined in Section 3.3) that the Company may from time to time issue after the date of
this Agreement (the “Right of Participation”). 
 3.2.    Pro Rata Share. Subject to
Section 2.3(iii) of the Share Purchase Agreement, a Participation Rights Holder’s “Pro Rata Share” for purposes of the Right of Participation is the ratio of (a) the number of Ordinary Shares
(calculated on a fully-diluted and as-converted basis) held by such Participation Rights Holder, to (b) the total number of Ordinary Shares of the Company then outstanding (calculated on a fully-diluted
and as-converted basis) immediately prior to the issuance of the New Securities giving rise to the Right of Participation. 

3.3.    New Securities. “New Securities” shall mean any Series A Preferred Shares, Ordinary Shares
or other voting shares of the Company and rights, options or warrants to purchase such Series A Preferred Shares, Ordinary Shares and securities of any type whatsoever that are, or may become, convertible or exchangeable into such Series A Preferred
Shares, Ordinary Shares or other voting shares, provided, however, that the term “New Securities” shall not include the Exempted Securities (as defined in the Company’s Amended and Restated Memorandum of
Association). 
 3.4.    Procedures. 

(a)    First Participation Notice. In the event that the Company proposes to undertake an issuance of New
Securities (in a single transaction or a series of related transactions), it shall give to each Participation Rights Holder written notice of its intention to issue New Securities (the “First Participation Notice”), describing the
amount and type of New Securities, the price and the general terms upon which the Company proposes to issue such New Securities. Each Participation Rights Holder shall have twenty (20) Business Days from the date of receipt of any such First
Participation Notice (the “First Participation Period”) to agree in writing to purchase such Participation Rights Holder’s Pro Rata Share of such New Securities for the price and upon the terms and conditions specified in the
First Participation Notice by giving written notice to the Company and stating therein the quantity of New Securities to be purchased (not to exceed such Participation Rights Holder’s Pro Rata Share). If any Participation Rights Holder fails to
so agree in writing within such twenty (20) Business Days period to purchase such Participation Rights Holder’s full Pro Rata Share of an offering of New Securities, then such Participation Rights Holder shall forfeit the right hereunder
to purchase that part of its Pro Rata Share of such New Securities that it did not agree to purchase. 

  
 15 

 (b)    Second Participation Notice; Oversubscription. If any
Participating Rights Holder fails or declines to exercise its Right of Participation in accordance with subsection (a) above, the Company shall promptly give notice (the “Second Participation Notice”) to other Participating
Rights Holders who exercised their Right of Participation (the “Right Participants”) in accordance with subsection (a) above. Each Right Participant shall have ten (10) Business Days from the date of receipt of the Second
Participation Notice (the “Second Participation Period”) to notify the Company of its desire to purchase more than its Pro Rata Share of the New Securities, stating the number of the additional New Securities it proposes to buy (the
“Additional Number”). If, as a result thereof, such oversubscription exceeds the total number of the remaining New Securities available for purchase, each oversubscribing Right Participant will be cut back by the Company with
respect to its oversubscription to that number of remaining New Securities equal to the lesser of (x) the Additional Number and (y) the product obtained by multiplying (i) the number of the remaining New Securities available for
subscription by (ii) a fraction, the numerator of which is the number of Ordinary Shares (calculated on a fully-diluted and as-converted basis) held by such oversubscribing Right Participant and the
denominator of which is the total number of Ordinary Shares (calculated on a fully-diluted and as-converted basis) held by all the oversubscribing Right Participants. 

(c)    Each Right Participant who exercises its Right of Participation hereunder by delivering aforesaid notice shall be
obligated to buy such number of New Securities in accordance with the terms of Section 3.4 and the Company shall so notify the Right Participants within ten (10) Business Days following the date of the Second
Participation Notice. The transaction in connection with the New Securities shall be consummated within forty-five (45) days after the expiration of the Second Participation Period. 

3.5.    Failure to Exercise. Upon the expiration of the Second Participation Period, the Company shall have ninety
days (90) days thereafter to sell the New Securities described in the First Participation Notice (with respect to the remaining New Securities) at the same or higher price and upon non-price terms not
materially more favorable to the purchasers thereof than specified in the First Participation Notice, provided that the prospective purchaser of such New Securities shall comply with this Agreement and the Restated Articles, as maybe amended from
time to time. In the event that the Company has not issued and sold such New Securities within such ninety days (90) day period, then the Company shall not thereafter issue or sell any New Securities without again first offering such New
Securities to the Participation Rights Holders pursuant to this Section 3. 

3.6.    Termination. The provisions set forth under this Section 3 shall terminate upon
the earlier to occur of (i) the closing of a Liquidation Event; and (ii) immediately prior to the consummation of the Qualified Initial Public Offering. 

4.    TRANSFER RESTRICTIONS. 

4.1.    Certain Definitions. For purposes of this Section 4, “Ordinary
Shares” means (i) the Company’s outstanding Ordinary Shares, (ii) the Ordinary Shares issued or issuable upon conversion of the Company’s outstanding Series A Preferred Shares, (iii) the Ordinary Shares issuable
upon exercise of outstanding options or warrants and (iv) the Ordinary Shares issuable upon conversion of any outstanding convertible securities; “Series A Preferred Shareholder” means the holder of Series A Preferred Shares of
the Company; 

  
 16 

 
“Ordinary Shareholder” means a holder of any ordinary share of the Company other than Series A Preferred Shareholders; and “Shareholder” means a Series A
Preferred Shareholder or an Ordinary Shareholder. 
 4.2.    Series A Preferred Shareholder’s
Right of First Refusal. Subject to Section 4.4 of this Agreement, if any Shareholder proposes to directly or indirectly sell, assign, pledge, hypothecate, transfer, or otherwise encumber or dispose of in any way or
otherwise grant any interest or right (“Transfer”) with respect to all or any part of any interest in any Ordinary Shares held by it to any third party (each, a “Selling Shareholder”), then such Selling Shareholder
shall promptly give written notice (the “Transfer Notice”) to the Company and each non-selling Series A Preferred Shareholder (the “Non-Selling
Shareholders”) prior to such Transfer. The Transfer Notice shall describe in reasonable detail the proposed Transfer including, without limitation, the number of Ordinary Shares to be Transferred (the “Offered Shares”), the
nature of such Transfer, the consideration to be paid, and the name and address of each prospective purchaser or transferee. The Non-Selling Shareholders may exercise their right of first refusal with respect
to the Offered Shares as follows: 
 (a)    Option of the Series A Preferred Shareholders. 

(i)    Each Non-Selling Shareholder shall have an option for a period of twenty
(20) Business Days from receipt of the Transfer Notice (the “Series A Preferred Shareholders’ First Refusal Period”) to elect to purchase the Offered Shares at the same price and subject to the same terms and
conditions as described in the Transfer Notice (the “Series A Preferred Shareholders’ Right of First Refusal”). Each Non-Selling Shareholder may exercise the Series A
Preferred Shareholders’ Right of First Refusal and purchase all or any portion of the Offered Shares by notifying the Selling Shareholder, the Company and each other Non-Selling Shareholder in writing
(the “Series A Preferred Shareholders’ First Refusal Notice”) before expiration of Series A Preferred Shareholders’ First Refusal Period as to the number of shares that it wishes to purchase. The Series A
Preferred Shareholders’ First Refusal Notice shall set forth the number of Offered Shares that such Non-Selling Shareholder wishes to purchase, which amount shall not exceed the First Refusal Allotment
(as defined below) of such Non-Selling Shareholder. 
 (ii)    In the event any
Non-Selling Shareholder elects not to purchase its First Refusal Allotment of the Offered Shares available under Section 4.2(a)(i) within the Series A Preferred Shareholders’
First Refusal Period, then the Selling Shareholder shall promptly give written notice (the “Series A Preferred Shareholders’ Overallotment Notice”) to each Series A Preferred Shareholder that has elected to purchase all of its
First Refusal Allotment of the Offered Shares (each a “Fully Participating Series A Preferred Shareholder”), which notice shall set forth the number of remaining Offered Shares not purchased by the other Non-Selling Shareholders (“Series A Preferred Shareholders’ Overallotment Shares”), and shall offer the Fully Participating Series A Preferred Shareholders the right to acquire its First
Refusal Allotment of the Series A Preferred Shareholders’ Overallotment Shares. Each Fully Participating Series A Preferred Shareholder shall have five (5) Business Days after receipt of the Series A Preferred Shareholders’
Overallotment Notice (the “Series A Preferred Shareholders’ Overallotment Period”) to deliver a written notice to the Selling Shareholder (the “Participating Series A Preferred Shareholders’ Overallotment
Notice”) of its election to purchase its First Refusal Allotment of the Series A Preferred Shareholders’ Overallotment Shares on the same terms and conditions as set forth in the Transfer Notice, which such Participating Series A
Preferred Shareholders’ Overallotment Notice shall also indicate the maximum number of the Series A Preferred Shareholders’ Overallotment Shares that such Fully Participating Series A Preferred Shareholder will purchase in the event that
any other Fully Participating Series A Preferred Shareholder elects not to purchase its First Refusal Allotment of the Series A Preferred Shareholders’ Overallotment Shares. 

  
 17 

 (b)    First Refusal Allotment. Each Non-Selling Shareholder shall have the right to purchase that number of the Offered Shares or Series A Preferred Shareholders’ Overallotment Shares, as the case may be (the “First Refusal
Allotment”), equivalent to the product obtained by multiplying the aggregate number of the Offered Shares or Series A Preferred Shareholders’ Overallotment Shares, as the case may be, by a fraction, the numerator of which is the number
of Ordinary Shares (on an as-converted basis) held by such Non-Selling Shareholder at the time of the transaction and the denominator of which is the total number of
Ordinary Shares (on an as-converted basis) owned by all Non-Selling Shareholders at the time of the transaction who have the right of first refusal to purchase the
applicable shares and have elected to participate in such right of first refusal purchase. A Non-Selling Shareholder shall not have a right to purchase any of the Offered Shares or Series A Preferred
Shareholders’ Overallotment Shares, as applicable, unless it exercises its right of first refusal within the Series A Preferred Shareholders First Refusal Period or the Series A Preferred Shareholders’ Overallotment Period, as applicable,
to purchase up to all of its First Refusal Allotment of the Offered Shares or Series A Preferred Shareholders’ Overallotment Shares, as applicable. 

(c)    Purchase Price and Payment. The purchase price for the Offered Shares to be purchased by the Non-Selling Shareholders exercising their right of first refusal will be the price set forth in the Transfer Notice, but will be payable as set forth below. If the purchase price in the Transfer Notice includes
consideration other than cash, the cash equivalent value of the non-cash consideration will be as previously determined by the Board in good faith (including affirmative votes of the Series A Directors) or by
a third party appraisal institution engaged by the Board, which determination will be binding upon the Company, the Selling Shareholder and the Non-Selling Shareholders, absent fraud or error. The transaction
shall be closed within forty-five (45) days following the date of the Transfer Notice and the payment of the purchase price shall be made by wire transfer or check as directed by the Selling Shareholder. 

(d)    Expiration Notice. Within five (5) days after the expiration of the Series A Preferred
Shareholders’ Overallotment Period, the Company will give written notice (the “First Refusal Expiration Notice”) to the Selling Shareholder and the Non-Selling Shareholders specifying
either (i) that all of the Offered Shares were subscribed by the Non-Selling Shareholders exercising their rights of first refusal, or (ii) that the
Non-Selling Shareholders have not subscribed for all of the Offered Shares in which case the First Refusal Expiration Notice will specify the Co-Sale Pro Rata Portion
(as defined below) of the remaining Offered Shares for the purpose of the co-sale right of the holders of the Series A Preferred Shares described in the Section 4.3 below. 

(e)    Rights of a Selling Shareholder. If any Non-Selling Shareholder
exercises its right of first refusal to purchase the Offered Shares, then, upon the date the notice of such exercise is given by the Non-Selling Shareholder, the Selling Shareholder will have no further rights
as a holder of such Offered Shares except the right to receive payment for such Offered Shares from such Non-Selling Shareholder in accordance with the terms of this Agreement, and the Selling Shareholder will
forthwith cause all certificate(s) evidencing such Offered Shares to be surrendered to the Company for cancellation and deliver to the Company a duly executed share transfer in respect of the Offered Shares to be transferred to such Non-Selling Shareholder, and the Company shall update its register of members accordingly. 

  
 18 

 4.3.    Series A Preferred Shareholder’s Co-Sale Right. In the event that the Non-Selling Shareholders have not exercised their right of first refusal with respect to any or all of the Offered Shares, then the
remaining Offered Shares not subscribed for under the right of first refusal pursuant to Section 4.2 above shall be subject to co-sale rights under this
Section 4.3 and each Series A Preferred Shareholder who have not exercised any of its right of first refusal with respect to the Offered Shares shall have the right, exercisable upon written notice to the Selling
Shareholder, the Company and each other Series A Preferred Shareholder (the “Co-Sale Notice”) within twenty (20) Business Days after receipt of First Refusal Expiration Notice (the
“Co-Sale Right Period”), to participate in such sale of the Offered Shares on the same terms and conditions as set forth in the Transfer Notice. The
Co-Sale Notice shall set forth the number of Ordinary Shares (on as-converted basis) that such participating Series A Preferred Shareholder wishes to include in such
sale or transfer, which amount shall not exceed the Co-Sale Pro Rata Portion (as defined below) of such Series A Preferred Shareholder. To the extent one or more of the Series A Preferred Shareholder exercise
such right of participation in accordance with the terms and conditions set forth below, the number of Ordinary Shares that such Selling Shareholder may sell in the transaction shall be correspondingly reduced. The
co-sale right of each Series A Preferred Shareholder shall be subject to the following terms and conditions: 

(a)    Co-Sale Pro Rata Portion. Each Series A Preferred Shareholder may
sell all or any part of that number of Ordinary Shares held by it that is equal to the product obtained by multiplying (x) the aggregate number of the Offered Shares subject to the co-sale right hereunder
by (y) a fraction, the numerator of which is the number of Ordinary Shares (on an as-converted basis) owned by such Series A Preferred Shareholder at the time of the sale or transfer and the denominator
of which is the combined number of Ordinary Shares (on an as-converted basis) at the time owned by all Series A Preferred Shareholders who elect to exercise their
co-sale rights (if any Series A Preferred Shareholder does not elect to exercise the co-sale right to the full extent then its Ordinary Shares (on as-converted basis) for calculation in the denominator shall be proportionately reduced) and the Selling Shareholder (“Co-Sale Pro Rata Portion”). 

(b)    Transferred Shares. Each participating Series A Preferred Shareholder shall effect its participation in the
sale by promptly delivering to the Selling Shareholder for transfer to the prospective purchaser one or more certificates, in addition to a duly executed instrument of transfer which represent: 

(i)    the number of Ordinary Shares which such Series A Preferred Shareholder elects to sell; 

(ii)    that number of Series A Preferred Shares which is at such time convertible into the number of Ordinary Shares
that such Series A Preferred Shareholder elects to sell; provided in such case that, if the prospective purchaser objects to the delivery of Series A Preferred Shares in lieu of Ordinary Shares, such Series A Preferred Shareholder shall
convert such Series A Preferred Shares into Ordinary Shares and deliver Ordinary Shares as provided in subsection 4.3(b)(i) above. The Company agrees to make any such conversion concurrent with the actual transfer of such shares to the purchaser; or

  
 19 

 (iii)    a combination of the above. 

(c)    Payment to Series A Preferred Shareholder. The share certificate or certificates that the participating
Series A Preferred Shareholder delivers to the Selling Shareholder pursuant to Section 4.3(b) shall be surrendered to the Company for cancellation and the register of members of the Company shall be updated in consummation
of the sale of the Offered Shares pursuant to the terms and conditions specified in the Transfer Notice, and the Selling Shareholder shall concurrently therewith remit to such Series A Preferred Shareholder that portion of the sale proceeds to which
such Series A Preferred Shareholder is entitled by reason of its participation in such sale. To the extent that any prospective purchaser or purchasers prohibits such assignment or otherwise refuses to purchase any shares or other securities from a
Series A Preferred Shareholder exercising its co-sale right hereunder, the Selling Shareholder shall not sell to such prospective purchaser or purchasers any Ordinary Shares unless and until, simultaneously
with such sale, the Selling Shareholder shall purchase such shares or other securities from such Series A Preferred Shareholder. 

(d)    Right to Transfer. To the extent the Series A Preferred Shareholders do not elect to purchase, or to
participate in the sale of, any or all of the Offered Shares subject to the Transfer Notice, the Selling Shareholder may, not later than ninety (90) days following delivery to the Company and each of the Series A Preferred Shareholders of the
Transfer Notice, conclude a transfer of the remaining Offered Shares covered by the Transfer Notice and not elected to be purchased by the Non-Selling Shareholders, which in each case shall be on substantially
the same terms and conditions as those described in the Transfer Notice. In the event the Selling Shareholder does not consummate the sale of such Offered Shares within ninety (90) business days in accordance with this
Section 4.3(d), the rights of the Series A Preferred Shareholders under Sections 4.2 and 4.3 shall be re-invoked and shall be applicable to each subsequent disposition
of such Offered Shares by the Selling Shareholder until such rights lapse in accordance with the terms of this Agreement. The Selling Shareholders shall cause any prospective purchaser of such shares to comply with this Agreement and Restated
Articles, as maybe amended from time to time. Any proposed transfer on terms and conditions which are materially different from those described in the Transfer Notice, as well as any subsequent proposed transfer of any Ordinary Shares by the Selling
Shareholder, shall again be subject to the right of first refusal of the Non-Selling Shareholders and the co-sale right of the Series A Preferred Shareholder and shall
require compliance by the Selling Shareholder with the procedures described in Sections 4.2 and 4.3 of this Agreement. 

4.4.    Permitted Transfers. Notwithstanding anything to the contrary contained herein, the right of first refusal
and co-sale rights of the Series A Preferred Shareholder as set forth in Section 4.2 and Section 4.3 above and the transfer restrictions set forth in
Section 4.5 below shall not apply to (a) any sale or transfer of Ordinary Shares to the Company pursuant to a repurchase right or right of first refusal held by the Company in the event of a termination (either
voluntary or involuntary) of employment or consulting relationship; and (b) any transfer by an Ordinary Shareholder of Ordinary Shares held by such Ordinary Shareholder as of the date hereof to its Affiliates, to trusts for the benefit of such
Ordinary Shareholder or such Ordinary Shareholder’s parents, children or spouse, for bona fide estate planning purposes, provided that the Ordinary Shareholder continues to exercise effective control over said Ordinary Shares including voting
rights (each transferee pursuant to the foregoing subsections (a) or (b), a “Permitted Transferee”); provided that adequate documentation therefor is provided to the Series A Preferred Shareholders to their satisfaction
and that any such Permitted Transferee agrees in writing to be bound by this Agreement in place of the relevant transferor; provided, further, that such transferor shall remain liable for any breach by such Permitted Transferee of any
provision hereunder. 

  
 20 

 4.5.    Prohibited Transfers. 

(a)    Except for transfers by any Investor to its Controlled Affiliates, until the earlier of (i) the Qualified
Initial Public Offering and (ii) second (2nd) anniversary of the Initial Closing, none of the Shareholders shall, without the prior written approval of the holders of [***] percent ([***]%)
of the Series A Preferred Shares, Transfer through one or a series of transactions any Company securities held by him to any person. 

(b)    Any attempt by a party to sell or transfer any share of the Company in violation of this
Section 4 shall be void and the Company hereby agrees it will not effect such a transfer nor will it treat any alleged transferee as the holder of such shares without the requisite written consent. 

4.6.    Restriction on Indirect Transfers. The Parties agree that the transfer restrictions set out in this
Section 4 shall not be circumvented or otherwise avoided by the holding of any Equity Securities of the Company indirectly through a company or other entity that can itself be sold in order to dispose of an interest in the
Equity Securities of the Company free of such restrictions. Any transaction or Transfer directly or indirectly of shares of a shareholder of the Company or of any company (or other entity) having control over such shareholder of the Company shall be
treated as a transfer of the Equity Securities of the Company held by that Shareholder, and the provisions of this Agreement that apply in respect of the transfer of Equity Securities of the Company shall apply to such transfer. 

4.7.    Legend. 

(a)    Each certificate representing the Ordinary Shares shall be endorsed with the following legend: 

“THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OF THE UNITED STATES, AS AMENDED.
THE SALE, PLEDGE, HYPOTHECATION OR TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS SUBJECT TO CERTAIN RESTRICTIONS ON TRANSFER SET FORTH IN A SHAREHOLDERS AGREEMENT, A COPY OF WHICH MAY BE OBTAINED UPON WRITTEN REQUEST TO THE SECRETARY
OF THE COMPANY.” 
 (b)    Each party agrees that the Company may instruct its transfer agent to impose transfer
restrictions on the shares represented by certificates bearing the legend referred to in Section 4.7(a) above to enforce the provisions of this Agreement and the Company agrees to promptly do so. The legend shall be removed
upon termination of the provisions of this Section 4. 

  
 21 

 4.8.    Term. The provisions under this
Section 4 shall terminate upon the earlier to occur of (i) the closing of a Liquidation Event; and (ii) immediately prior to the consummation of the Qualified Initial Public Offering. 

5.    ASSIGNMENT AND AMENDMENT. 

5.1.    Assignment and Amendment. Notwithstanding anything herein to the contrary: 

(a)    Information Rights; Registration Rights. The Information Rights and Inspection Rights under
Section 1.1 may be assigned to any holder of Series A Preferred Shares, and the registration rights of the Holders under Section 2 may be assigned to any Holder or to any person acquiring
Registrable Securities, in each case, in accordance with the terms of this Agreement; provided, however, that in either case no party may be assigned any of the foregoing rights unless the Company is given written notice by the
assigning party, stating the name and address of the assignee and identifying the securities of the Company as to which the rights in question are being assigned; provided further, that any such assignee shall receive such assigned
rights subject to all the terms and conditions of this Agreement, including without limitation the provisions of this Section 5. 

(b)    Right of Participation; Right of First Refusal; Co-Sale Right. The
rights of each holder of Series A Preferred Shares under Section 3 and each holder of Series A Preferred Shares under Section 4 are fully assignable in connection with a transfer of shares of the
Company by such holder of Series A Preferred Shares in accordance with the terms of this Agreement; provided, however, that no party may be assigned any of the foregoing rights unless the Company is given written notice by the holder
of the Series A Preferred Shares, stating the name and address of the assignee and identifying the securities of the Company as to which the rights in question are being assigned; and provided further, that any such assignee shall
receive such assigned rights subject to all the terms and conditions of this Agreement. 
 5.2.    Amendment of
Rights. Any provision in this Agreement may be amended and the observance thereof may be waived (either generally or in a particular instance and either retroactively or prospectively), only by the written consent of (a) the Company; and
(b) the persons or entities holding at least [***] percent ([***]%) of the Series A Preferred Shares then outstanding and their permitted assigns; provided, however, that (i) no provision hereof may be amended or waived, in
each case, in any way which would adversely affect the rights of one holder of Series A Preferred Shares hereunder in a manner disproportionate to any adverse effect such amendment or waiver would have on other such holder without the consent of
such disproportionately affected holder and (ii) any holder of Series A Preferred Shares may waive any of its rights hereunder without obtaining the consent of any other holders of Series A Preferred Shares or their assigns; provided, further,
however, that Sections 1.1(a), 1.2(a), 7.1(m) and 9.5 of this Agreement shall not be amended or waived without the express written consent of Ascendis and Sections 1.1(a), 1.2(b), 7.1(m) and
9.5 of this Agreement shall not be amended or waived without the express written consent of Vivo Capital. Any amendment or waiver effected in accordance with this Section 5.2 shall be binding upon the Company,
the holders of Series A Preferred Shares and their respective assigns. The Company shall give prompt written notice of any amendment, termination, or waiver hereunder to any party that did not consent in writing thereto. 

  
 22 

 6.    CONFIDENTIALITY AND
NON-DISCLOSURE. 
 6.1.    Shareholder’s
Confidentiality Obligation. Each Investor agrees that such Investor will, and will cause its Affiliates and Representatives to, keep confidential and will not disclose, divulge, or use for any purpose (other than for its investment in the
Company) the terms of this Agreement and any confidential information obtained from the Group Companies (including notice of the Company’s intention to file a registration statement), unless such confidential information (a) is known or
becomes known to the public in general (other than as a result of a breach of this Subsection by such Investor), (b) is or has been independently developed or conceived by such Investor without use of the Company’s confidential
information, or (c) is or has been made known or disclosed to such Investor by a third party without a breach of any obligation of confidentiality such third party may have to the Company; provided, however, that an Investor may
disclose confidential information (i) to its Affiliates, attorneys, accountants, consultants, and other professionals to the extent necessary to obtain their services in connection with monitoring its investment in the Company; (ii) to any
prospective purchaser of any Registrable Securities from such Investor, if such prospective purchaser agrees to be bound by the provisions of this Subsection; (iii) to any existing or prospective Affiliate, partner, member,
stockholder, or wholly owned subsidiary of such Investor in the ordinary course of business, provided that such Investor informs such Person that such information is confidential and directs such Person to maintain the confidentiality of such
information; or (iv) as may otherwise be required by law, regulation, rule, court order or subpoena (including the rules and regulations of the U.S. Securities and Exchange Commission), provided that such Investor promptly notifies the
Company of such disclosure and takes reasonable steps to minimize the extent of any such required disclosure. For purposes of this Agreement, “Affiliate” shall mean, with respect to any Person, another Person which controls, is
controlled by or is under common control with such Person. A Person shall be deemed to control another Person if such Person possesses, directly or indirectly, the power to direct or cause the direction of the management and policies of such Person,
whether through the ownership of voting securities, by contract or otherwise. For the avoidance of doubt, any breach of the confidentiality and non-use obligations by any of its Affiliates or Representative
shall be deemed a breach by such Investor, for which such Investor shall be fully responsible. 
 6.2.    Press
Releases, Etc. No announcement regarding any of the Financing Terms in a press release, conference, advertisement, announcement, professional or trade publication, mass marketing materials or otherwise to the general public may be made without
the Major Investors’ prior written consent (which consent shall not be unreasonably withheld), except as may otherwise be required by law, regulation, rule, court order or subpoena (including the rules and regulations of the U.S. Securities and
Exchange Commission). Following the execution of this Agreement, the Major Investors will issue an initial press release, the form and timing of which shall be agreed between the Major Investors. 

6.3.    Other Information. The provisions of this Section 6 shall be in addition to, and
not in substitution for, the provisions of any separate nondisclosure agreement executed by any of the parties with respect to the transactions contemplated hereby. 

6.4.    Notices. All notices required under this section shall be made pursuant to
Section 12.1 of this Agreement. 

  
 23 

 7.    PROTECTIVE PROVISIONS. 

7.1.    Approval by Shareholders. In addition to such other limitations as may be provided in the
Restated Articles, so long as at least twenty-five percent (25%) of the Series A Preferred Shares issued at the Initial Closing remain outstanding, none of the Group Companies shall, and the Founders shall procure that each of the Group Companies
shall not, directly or indirectly, whether in a single transaction or series of related transactions, whether by amendment, merger, consolidation or otherwise, carry out any of the following actions except with the prior written approval of holders
of more than [***] percent ([***]%) of the Series A Preferred Shares then outstanding, voting as a separate class: 

(a)    any repeal, amendment, modification or change of the memorandum or the articles or other similar constitutive
documents of any Group Company; 
 (b)    any amendment, modification or change of any rights, preferences, privileges
or powers of, or any restrictions provided for the benefit of, the Series A Preferred Shares or any amendment, modification or change of any rights, powers or benefit attached to the Ordinary Shares or other classes or series of shares having the
effect of or may result in any rights, preferences, privileges or powers of the Series A Preferred Shares being prejudiced; 

(c)    liquidation, dissolution, winding up or reorganization of any Group Company, or any Liquidation Event; 

(d)    any issue, allotment or grant of any options, warrants or similar rights conferring on any Person the right to
acquire, any shares, securities or equity interest in the Group Companies (except where such issue, allotment or grant is incidental to the exercise of conversion rights applicable to the Series A Preferred Shares or pursuant to the pre-approved share option plans, share incentive scheme or other schemes and agreements of similar nature); 

(e)    any action that authorizes, creates or issues shares of any class or series, or other securities of whatever
description, or reclassifies or converts any issued or outstanding shares of the Company into shares, having rights, priority or preferences superior to or on a parity with the Series A Preferred Shares, whether in terms of voting rights, dividends
or amounts payable in the event of any voluntary or involuntary liquidation or distribution of the Company or otherwise; 

(f)    any increase or decrease in the number of authorized Series A Preferred Shares or Ordinary Shares; 

(g)    any repurchase or redemption of any shares or other securities of the Company other than repurchases of shares from
former employees, officers, directors, consultants or other persons who performed services for the Company or any Group Company in connection with the cessation of such employment or service pursuant to the ESOP Plan (as defined below); 

(h)    the declaration or payment of a dividend on any share or other securities of any Group Company and any change of
dividend policy of any Group Company; 
 (i)    any action that creates, or authorizes the creation of, any debt
security; 

  
 24 

 (j)    changing the principal business of the Group Companies, entering
into any new line of business, or exiting the current line of business; 
 (k)    the creation, adoption and material
amendment of any equity incentive plan or equivalent by the Group Companies (including total amount of options, exercise price and term of exercise); 

(l)    any increase or decrease in the authorized number of members of the board of directors of any Group Company; 

(m)    sell, assign, license, sublicense, pledge or encumber material technology or intellectual property to any third
party; and 
 (n)    any agreement or commitment by any Group Company to do any of the foregoing. 

Notwithstanding anything to the contrary contained herein, where any act listed in clauses (a) through (n) above requires a resolution of
the Members, and if the shareholders vote in favour of such act but the approval of the holders of more than [***] percent ([***]%) of the outstanding Series A Preferred Shares has not yet been obtained in accordance with this
Section 7.1, the holders of Series A Preferred Shares that vote against such resolution shall have, in such vote at a meeting of the shareholders, the voting rights equal to the aggregate voting power of all the
shareholders of the Company who voted in favour of the resolution plus one. 
 7.2.    Approval by Board of
Directors. In addition to such other limitations as may be provided in the Restated Articles, so long as the holders of Series A Preferred Shares are entitled to elect a Series A Director, none of the Group Companies shall, directly or
indirectly, whether in a single transaction or series of related transactions, whether by amendment, merger, consolidation or otherwise, except with the prior written approval of each of the Series A Directors: 

(a)    make any loan or advance to, or own any share or other securities of, any subsidiary or other corporation,
partnership, or other entity unless it is wholly owned by a Group Company; 
 (b)    make any loan or advance to any
person, including, any employee or director of any Group Company, except advances and similar expenditures in the ordinary course of business or under the terms of an equity incentive plan approved by the Board; 

(c)    guarantee any indebtedness except for trade accounts of the Group Companies or any subsidiary arising in the
ordinary course of business; 
 (d)    make any investment inconsistent with any investment policy approved by the
Board; 
 (e)    incur any aggregate indebtedness in excess of US$1,000,000 that is not already included in a
Board-approved budget, other than trade credit incurred in the ordinary course of business; 

  
 25 

 (f)    enter into or be a party to any transaction with any director,
officer or employee of the Group Companies or any “associate” (as defined in Rule 12b-2 promulgated under the Exchange Act) of any such person, or with any shareholder or its affiliates or any
director, officer or employee of such shareholder or its affiliates or any “associate” of any such person, other than transactions made in the ordinary course of business and pursuant to reasonable requirements of the Group Companies’
business and upon fair and reasonable terms that are approved by a majority of the Board; 
 (g)    hire, fire, or
change the compensation of the executive officers, and approve any and all option grants to the executive officers of any Group Company; 

(h)    sell, assign, license, sublicense, pledge or encumber material technology or intellectual property of any Group
Company; 
 (i)    enter into any corporate strategic relationship involving the payment, contribution or assignment by
any Group Company or to any Group Company of assets greater than US$500,000; or 
 (j)    any agreement or commitment
by any Group Company to do any of the foregoing. 
 7.3.    Termination. The provisions set forth under this
Section 7 shall terminate upon the earlier to occur of (i) the closing of a Liquidation Event; and (ii) immediately prior to the consummation of the Qualified Initial Public Offering. 

8.    DRAG ALONG 

8.1.    In the event that (i) the holders of at least [***] percent ([***]%) of the outstanding Ordinary Shares (on an
as-converted basis) (the “Approving Shareholders”); and (ii) the Board of Directors approve in writing, to sell or transfer the shares or assets of any Group Company in any transaction or
a series of related transactions that would qualify as a Liquidation Event, to a bona fide third party, or a group of bona fide related parties (the “Change of Control”), then the Company shall promptly notify each of the remaining
shareholders of the Company (the “Remaining Shareholders”, including without limitation, each of the holders of Ordinary Shares and Series A Preferred Shares) in writing of such vote, consent and/or agreement and the material terms
and conditions of such Change of Control, whereupon each Remaining Shareholder shall, in accordance with instructions received from the Company (the “Drag Along Instructions”), vote all of its voting securities of the Company in
favor of, otherwise consent in writing to, and/or otherwise sell or transfer all of their shares in such Change of Control (including without limitation tendering original share certificates for transfer, signing and delivering share transfer
certificates, share sale or exchange agreements, and certificates of indemnity relating to any shares in the share capital of the Company in the event that such Remaining Shareholder has lost or misplaced the relevant share certificate) on the same
terms and conditions as were agreed to by the Approving Shareholders.
 8.2.    Notwithstanding the foregoing, a
Remaining Shareholder will not be required to comply with Section 8.1 above in connection with any proposed Change of Control, unless the liability for indemnification, if any, of such Remaining Shareholder in the Change of
Control and for the inaccuracy of any representations and warranties made by the Company and/or its shareholders in connection with such Change of Control, is several and not joint with any other Person, and is proportionate to, and does not exceed,
the amount of consideration paid to such Remaining Shareholder in connection with such Change of Control. 

  
 26 

 8.3.    In furtherance of the foregoing, the Company is hereby expressly
authorized by each Remaining Shareholder to take any or all of the following actions on such Remaining Shareholder’s behalf (without receipt of any further consent by such Remaining Shareholder), provided such Remaining Shareholder fails to
take necessary actions as required under the Drag Along Instructions, to: (i) vote all of the voting securities of such Remaining Shareholder in favor of any such Change of Control and cause the director(s) appointed by such Remaining
Shareholder to vote in favor of any such Change of Control; (ii) otherwise consent on such Remaining Shareholder’s behalf to such Change of Control; (iii) sell all of such Remaining Shareholder’s shares in such Change of Control,
in accordance with the terms and conditions of this Section; and/or (iv) act as the Remaining Shareholder’s attorney in fact in relation to any such Change of Control and have the full authority to sign and deliver, on behalf of such
Remaining Shareholder, share transfer certificates, share sale or exchange agreements and certificates of indemnity relating to any shares in the share capital of the Company in the event that such Remaining Shareholder has lost or misplaced the
relevant share certificate. Notwithstanding anything to the contrary in the Shareholders Agreement, none of the transfer restrictions set forth in the Shareholders Agreement shall apply in connection with such Change of Control. 

8.4.    Upon written notice to the Company from the Approving Shareholders, the Company shall initiate a process intended
to result in a Change of Control and shall cause its officers, employees, consultants, counsel and advisors to take all necessary and appropriate actions to facilitate a Change of Control. 

9.    COVENANTS; UNDERTAKINGS 

9.1.    Controlled Foreign Corporation. Each year, based on and in reliance of the information provided by the
shareholders of the Company (the “Shareholders”) within a reasonable time after being requested, the Company shall make due inquiry with its tax advisors regarding whether the Company or any of its Subsidiaries is treated as a
“Controlled Foreign Corporation” (“CFC”) as defined in the United States Internal Revenue Code of 1986 (the “Code”), whether any portion of the Company’s or any of its Subsidiaries’ income is (a)
“Subpart F Income” (as defined in Section 952 of the Code) (“Subpart F Income”) or (b) “global intangible low-taxed income” (as defined in Section 951A(b) of the
Code) (“GILTI”) and each Shareholder’s share, if any, of such Subpart F Income and/or GILTI (regardless of whether a Shareholder is a “United States Shareholder” or not). Upon written request of any Investor who is a
United States Shareholder (or whose direct or indirect owners are United States Shareholders) with respect to the Company or any Group Company within the meaning of Section 951(b) of the Code, the Company will (i) use best efforts to
provide in writing such information as is in its possession and reasonably available concerning its shareholders and affiliates to assist such Investor in determining whether the Company or any Group Company is a CFC and (ii) provide such
Investor with reasonable access to such information as is in the Company’s or Group Company’s possession and reasonably available as may be required by such Investor (A) to determine the Company’s (or Group Company’s) status
as a CFC, (B) to determine whether such Investor is required to report its pro rata portion of the Company’s (or Group Company’s) “Subpart F income” (as defined in Section 952 of the Code) on its United States
federal income tax return, or (C) to allow such Investor to otherwise comply with applicable United States federal income tax laws (including with respect to the making of any determinations under Section 951A of the Code); provided
that the Company may require such Investor to enter into a confidentiality agreement in customary form. 

  
 27 

 9.2.    Passive Foreign Investment Company. The Company shall use
commercially reasonable efforts to avoid being a “passive foreign investment company” within the meaning of Section 1297 of the Code (“PFIC”) for the current and any future taxable year. The Company shall make due
inquiry with its tax advisors on at least an annual basis regarding its status as a PFIC, and if the Company is informed by its tax advisors that it has become a PFIC, or that it is likely that the Company will be classified as a PFIC for any
taxable year, the Company shall promptly notify each Investor of such status or risk, as the case may be, in each case no later than forty-five (45) days following the end of the Company’s taxable year. The Company shall provide its
Investors with annual financial information in the form to the reasonable satisfaction of such Investor as soon as reasonably practicable following the end of each taxable year of such Investor (but in no event later than forty-five (45) days
following the end of each such taxable year), and shall, upon the request in writing by any Investor, provide such Investor with access to such other information, as is in the Company’s possession and reasonably available, as may be required
for purposes of filing U.S. federal income tax returns in connection with a qualified electing fund election or other tax filing in respect of the Company’s status of a PFIC. In the event that it is determined by the Company’s or such
Investor’s tax advisors that the control documents in place between one or more of the Company’s wholly owned Subsidiaries and/or the Company, on the one hand, and any of the Group Companies organized in the PRC that is not a wholly
foreign owned enterprise, on the other hand, do not allow the Company to look through the Group Companies to their assets and income for purposes of the PFIC rules and regulations under the Code, the Company shall use its best efforts to take
such actions as are reasonably necessary or advisable, including the amendment of such control documents, to qualify for such look-through treatment of the Group Companies under the PFIC rules and regulations under the Code. 

9.3.    Subsidiary Covenants. The Company shall at any time institute and shall keep in place arrangements
satisfactory to the Board such that the Company (i) will control the operations of any Group Company and (ii) will be permitted to properly consolidate the financial results for such entity in consolidated financial statements for the
Company prepared under the PRC GAAP and IFRS. The Company shall, and shall cause each Group Company and use its reasonably best efforts to cause such Group Company’s respective directors, officers, employees, agents and other persons acting on
its behalf or purporting to act on its behalf to, comply with the US Foreign Corrupt Practices Act, as amended, in all material respects. 

9.4.    Additional Subsidiary Covenants. The Company shall take all necessary actions to maintain its Subsidiaries,
as is necessary to conduct the Company’s business as conducted or as proposed to be conducted. The Company shall use its best efforts to cause each Subsidiary to comply in all material respects with all applicable laws, rules, and regulations.
All material aspects of such formation, maintenance and compliance of each Subsidiary shall be subject to the review, approval and oversight by the Board. 

  
 28 

 9.5.    Non-Compete.
Ascendis undertakes and covenants to the Company that commencing from the date of this Agreement, it will not, without the prior written consent of the Company, either on its own account or through any of his/its Controlled Affiliates, or in
conjunction with or on behalf of any other person: (i) carry out or be engaged in the research, development, manufacture or commercialization of [***] in the People’s Republic of China (including Hong Kong, Macao and Taiwan) (the
“Competing Business”); (ii) directly or indirectly own any interest in a third party engaged in the Competing Business other than holding in aggregate not more than [***] percent ([***]%) of the issued share capital of any entity
engaged in the Competing Business as a passive investor; (iii) solicit or entice away or attempt to solicit or entice away from any Group Company, any person, firm, company or organization who is a customer, client, employee, representative,
agent or correspondent of such Group Company or in the habit of dealing with such Group Company, or (iv) provide services to any entity engaged in the Competing Business [***]. For clarity; subsection (iv) shall not apply to services that
Ascendis provides to a competing company outside the Territory for the use outside of the Territory. For avoidance of the doubt, all activities performed pursuant to the following agreements shall not constitute engagement in the Competing Business
and neither Ascendis nor its Controlled Affiliates shall be deemed to have engaged in any Competing Business as a result of any activities performed under such agreements: (a) [***] and (b) [***]. In the event that any entity, in which Ascendis owns
directly or indirectly more than [***] percent ([***]%) of the issued share capital and/or Ascendis is not merely a passive investor, becomes [***] in the Competing Business, Ascendis shall decrease its holding in such entity to [***] percent
([***]%) [***] and in any event within [***] ([***]) months after the time when Ascendis comes to own directly or indirectly more than [***] percent ([***]%) of the issued share capital of such entity engaged in the Competing Business [***]. The
provisions of this Section 9.5 shall terminate upon the earlier to occur of (i) the closing of a Liquidation Event; or (ii) the termination of each of the Exclusive License Agreements dated the date hereof by and
among the Company and Ascendis Pharma Growth Disorders A/S, Ascendis Pharma Endocrinology Division A/S and Ascendis Pharma Bone Diseases A/S (the “Rights Agreements”). For clarity, nothing in this
Section 9.5 shall restrict or limit the ability of Ascendis or its Affiliates to fulfill or perform its obligations under any other agreement with the Company, including without limitation any Rights Agreement or any
clinical or commercial supply agreement entered into by Ascendis or its Affiliates with the Company. [***]. 

9.6.    Compliance. The Group Companies shall conduct their respective business as currently conducted or proposed
to be conducted in compliance with all applicable Laws of each relevant jurisdiction on a continuing basis. 

9.7.    Management. Vivo Capital shall be entitled to nominate the candidates for the Chief Executive Officer and
the Chief Business Officer of the Company to be approved by the Board. Effective as of the Initial Closing, Ms. Daisy XU and Dr. Dandan DONG shall serve as the founding Chief Executive Officer and Chief Business Officer of the Company to
work through tax related matters in the PRC, recruit CEO and key management team members of the Group Companies, design regulatory strategy, and perform other functions as approved by the Board. The Company shall reasonably compensate for the
services provided by Ms. Daisy XU and Dr. Dandan DONG to the Group Companies. The provisions of this Section 9.7 shall terminate upon the earlier to occur of (i) the closing of a Liquidation Event; and
(ii) immediately prior to the consummation of the Qualified Initial Public Offering. 

  
 29 

 9.8.    ESOP. As soon as practicable after the Initial Closing,
the Company shall cause an employee equity incentive plan (the “ESOP Plan”) to be duly adopted by the Board and shareholders of the Company, pursuant to which [***] Ordinary Shares (representing [***]% of the total number of
Ordinary Shares of the Company immediately after the Initial Closing on a fully diluted and as-converted basis) shall be reserved for future issuance to officers, directors, employees, consultants or service
providers of the Group Companies. The Company shall cause each of the grantees under the ESOP Plan to enter into such grant documents which shall provide the Company with a right of first refusal on grantee’s transfer of shares and shall
further provide that if the Company fails to exercise its right of first refusal, each of the Investors shall have a right of first refusal with respect to the shares not purchased by the Company, in accordance with its pro rata ownership of the
Company (on an as-converted basis), and if any Investor fails to exercise its right of first refusal with respect to such shares, it shall have the right to sell its pro rata shares together with the
transferring grantee. In addition, the Company shall ensure that each holder of the Ordinary Shares representing no less than one percent (1%) of the Company’s total outstanding Ordinary Shares on fully-diluted and as-converted basis shall execute a joinder agreeing to the terms of this Agreement. 

9.9.    D&O Insurance. The Company will purchase D&O insurance with a carrier and in an amount satisfactory
to the Board within 60 days of the Initial Closing. In the event any Group Company merges with another entity and is not the surviving corporation, or transfers all of its assets, proper provisions shall be made so that successors of such Group
Company assume such Group Company’s obligations with respect to indemnification of Directors. Upon request by either of the Major Investors, the other Group Companies will purchase D&O insurance with a carrier and in an amount satisfactory
to the board of directors of the relevant Group Company. 
 9.10.    Maintaining and Obtaining Licenses and Permits
for the Principal Business. As soon as practicable after the Initial Closing, each of the Group Companies shall (i) maintain in a timely manner all requisite Consents and Permits for conducting the Principal Business in compliance with all
material aspects with applicable Laws, and (ii) if so required by any applicable Laws, obtain additional Consents and Permits necessary for conducting the Principal Business as soon as possible but in any event no later than the time limit
required by the applicable Laws or the competent Governmental Authorities. 
 9.11.    Employment Agreement and
Confidentiality, Non-Competition and Intellectual Property Rights Agreements. The Group Companies shall cause each of their respective current and future employees to enter into an employment agreement in
form and substance satisfactory to the Major Investors. The Group Companies shall cause each of their respective current and future employees and consultants to enter into a confidentiality, non-competition
and proprietary information and inventions assignment agreement in form and substance satisfactory to the Major Investors. 

9.12.    Compliance & Anti-Corruption. Upholding ethical standards, acting with
integrity and in compliance with applicable laws and regulations, is essential to the Group Companies. The Group Companies undertakes to conduct its business in accordance with all applicable laws and regulations. The Company shall not (and shall
not permit any of its Subsidiaries or Affiliates or any of its or their respective directors, officers, managers, employees, independent contractors, representatives or agents to) promise, authorize or make any payment to, or otherwise contribute
any item of value to, directly or indirectly, to any third party, including any Non-U.S. Official (as (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the
“FCPA”)), in each case, in violation of the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. The Company shall (and shall cause each of its subsidiaries and affiliates to) maintain processes
and procedures designed to prevent any person working for or engaged by the Company and its subsidiaries and affiliates or any other third party in any way connected to the Company, from 

  
 30 

 
engaging in any activity, practice or conduct which would infringe any anti-bribery and anti-corruption laws, regulations and codes, including but not limited to the UK Bribery Act and the FCPA.
Furthermore, the Company shall (and shall cause each of its subsidiaries and affiliates to) maintain systems of internal controls (including, but not limited to, accounting systems, purchasing systems and billing systems) to ensure compliance with
the FCPA, the U.K. Bribery Act, or any other applicable anti-bribery or anti-corruption law. Upon request, the Company agrees to provide responsive information, documentation and/or certifications concerning its (and each of its Subsidiaries
and Controlled Affiliates) compliance with applicable anti-corruption laws. The Company shall promptly notify each Investor in writing if the Company suspects or becomes aware of any actual or potential fraud,
non-compliance, misconduct or enforcement action, and promptly take all appropriate steps to resolve and correct any identified non-conformity. The Company
undertakes to maintain adequate and accurate books and records to ensure compliance, including but not limited to using practices and normal systems and methodologies according to IFRS. The Company shall, and shall cause any direct or indirect
subsidiary or entity controlled by it, whether now in existence or formed in the future, to comply with the FCPA and any other applicable anti-corruption law. The Company shall use its best efforts to cause any direct or indirect subsidiary,
whether now in existence or formed in the future, to comply in all material respects with all applicable laws. 
 10.    Termination
and Consequences of Termination. 
 10.1.    Termination. 

(a)    This Agreement (i) may be terminated at any time by written agreement between each of the Major Investors;
and (ii) shall be automatically terminated upon the dissolution of the Company. 
 (b)    In addition, upon the
occurrence of any of the events listed in Section 10.1 (each, a “Termination Event”), the holders of [***] percent ([***]%) of the Series A Preferred Shares (excluding the Series A Preferred Shares held by
the Party in breach or subject to the Termination Event) (the “Terminating Party”) shall be entitled to terminate this Agreement, with immediate effect, by issuing a written notice to the other shareholders of the Company (the
“Non-Terminating Party”), with a copy to the Company, specifying the applicable Termination Event: 

(i)    if there is a material breach of Section 9.5 under this Agreement by the Non-Terminating Party; 
 (ii)    if any Major Investor files any petition or action
for relief under any bankruptcy, reorganization, insolvency or moratorium law or any other law for the relief of, or relating to, debtors, now or hereafter in effect, or makes any assignment for the benefit of creditors or takes any corporate action
in furtherance of any of the foregoing; 
 (iii)    if an involuntary petition is filed against any Major Investor
(unless such petition is dismissed or discharged within 60 days under any bankruptcy statute now or hereafter in effect), or a custodian, receiver, trustee, assignee for the benefit of creditors (or other similar official) is appointed to take
possession, custody or control of any property of such Major Investor; or 

  
 31 

 (iv)     if the Rights Agreements were wrongfully terminated by the Non-Terminating Party or terminated due to the Non-Terminating Party’s breach or failure to fulfill its obligations under the Rights Agreements. 

10.2.    Effect of Termination. Upon the termination of this Agreement, the Company shall be dissolved and
liquidated in accordance with the Restated Articles, the relevant Cayman Island Laws. The Shareholders shall take any and all lawful actions, including without limitation exercising their respective voting rights and causing their directors to
exercise their voting rights in the Board, to ensure the approval of the dissolution of the Company. Notwithstanding anything to the contrary, the provisions of Sections 6, 10, 11 and 12 shall survive the expiration or
early termination of this Agreement and the termination, dissolution or liquidation of the Company. 
 11.    INDEMNIFICATION.

 11.1.    General Indemnity. 

(a)    If a Party fails to perform any of its obligations under this Agreement (the “Breaching Party”),
then, following written notice by any other parties hereto (the “Non-Breaching Party”) and a ten (10) day opportunity to cure such breach (should it be capable of cure), the Breaching
Party shall indemnify such Non-Breaching Party and the Company for, all claims, losses, damages, liabilities, documented costs and expenses (including reasonable attorneys’ fees) (the
“Losses”) which have been incurred by such Non-Breaching Party or the Company in respect of a breach by a Breaching Party of any of its representations and warranties, covenants, undertakings,
or other obligations under this Agreement.
 (b)    NO PARTY SHALL BE LIABLE TO OTHER PARTIES, ITS RELATED PARTIES,
THEIR RESPECTIVE OFFICERS, DIRECTORS, AGENTS, REPRESENTATIVES OR EMPLOYEES WITH RESPECT TO ANY SUBJECT MATTER OF THIS AGREEMENT (OTHER THAN BREACH OF THE CONFIDENTIALITY OR NON-COMPETITION OBLIGATIONS
HEREUNDER) UNDER ANY CONTRACT, NEGLIGENCE, STRICT LIABILITY OR OTHER LEGAL OR EQUITABLE THEORY FOR ANY INCIDENTAL OR CONSEQUENTIAL DAMAGES OR LOST PROFITS EXCEPT FOR LOSSES ACTUALLY INCURRED IN THIRD PARTY CLAIM(S). 

11.2.    Claim Notice Procedure. 

Without limiting any other rights of the Non-Breaching Party in any way (including their rights to
pursue damages in respect of a claim for breach of any covenant or other obligation), any Non-Breaching Party shall have the right to make a claim for indemnity under this Agreement at any time after the date
hereof by issuing a written claim notice (the “Claim Notice”) to the Breaching Party. The Claim Notice shall describe the breach in question along with the Party’s determination of the following: 

(a)    the amount which would be necessary to put the Company and/or the
Non-Breaching Party, as the case may be, into the financial position which would have existed had there been no breach of any representations and warranties, covenants, undertakings, or other obligations in
question; and 

  
 32 

 (b)    all costs suffered or incurred by the Non-Breaching Party directly or indirectly, as a result of or in connection with such breach of representations and warranties, covenants, undertakings, or other obligations. 

11.3.    Payment under Claim Notice. 

Within fifteen (15) Business Days after receipt of a Claim Notice, the Breaching Party shall pay to the Company and/or the Non-Breaching Party all of the amounts specified in the Claim Notice. 

11.4.    No Deduction. 

All sums payable by the Breaching Party to the Company or the Non-Breaching Party under
Section 11 shall be paid free and clear of all deductions or withholdings whatsoever save only as may be required by law. If any such deductions or withholdings are required by law, the Breaching Party shall be obliged
to pay to the relevant person such sum as will, after deduction or withholding has been made, leave that person with the same amount as it would have been entitled to receive in the absence of any requirement to make a deduction or withholding. 

11.5.    Director Indemnification. 

To the fullest extent permitted by applicable laws, the Company shall indemnify and hold harmless any Director for any damage, demand, claim,
liability, obligation, loss, cost, expense (including, without limitation, the fees and disbursements of attorneys, accountants, and consultants), deficiency, interest, penalty, impositions, assessments or fines of any kind or nature, whether known
or unknown, fixed or contingent, arising out of or resulting from such Director’s service on the Board or any committee thereof. 

12.    GENERAL PROVISIONS. 

12.1.    Notices. Except as may be otherwise provided herein, all notices, requests, waivers and other
communications made pursuant to this Agreement shall be in writing and shall be conclusively deemed to have been duly given (a) when hand delivered to the other party, upon delivery; (b) when sent by facsimile at the number set forth in
Exhibit A hereto, upon receipt of confirmation of error-free transmission; (c) seven (7) Business Days after deposit in the mail as air mail or certified mail, receipt requested, postage prepaid and addressed to the other party as set
forth in Exhibit A; (d) four (4) Business Days after deposit with an international overnight delivery service, postage prepaid, addressed to the parties as set forth in Exhibit A with next-business day delivery guaranteed,
provided that the sending party receives a confirmation of delivery from the delivery service provider; or (e) when sent by email at the email address set forth in Exhibit A hereto, upon receipt of confirmation of receipt. Each person
making a communication hereunder by facsimile shall promptly confirm by telephone to the person to whom such communication was addressed each communication made by it by facsimile pursuant hereto but the absence of such confirmation shall not affect
the validity of any such communication. A party may change or supplement the addresses given above, or designate additional addresses, for purposes of this Section 12.1 by giving the other party written notice of the new
address in the manner set forth above. 

  
 33 

 12.2.    Entire Agreement. This Agreement and the Share Purchase
Agreement, any other Transaction Documents, together with all the exhibits hereto and thereto, constitute and contain the entire agreement and understanding of the parties with respect to the subject matter hereof and supersedes any and all prior
negotiations, correspondence, agreements, understandings, duties or obligations between the parties respecting the subject matter hereof. Capitalized terms which are not defined hereinto shall have the same meaning as such in the Share Purchase
Agreement. 
 12.3.    Governing Law. This Agreement shall be governed by and construed exclusively in accordance
with the laws of the Hong Kong Special Administrative Region without regard to principles of conflicts of law thereunder. 

12.4.    Severability. If any provision of this Agreement is found to be invalid or unenforceable, then such
provision shall be construed, to the extent feasible, so as to render the provision enforceable and to provide for the consummation of the transactions contemplated hereby on substantially the same terms as originally set forth herein, and if no
feasible interpretation would save such provision, it shall be severed from the remainder of this Agreement, which shall remain in full force and effect unless the severed provision is essential to the rights or benefits intended by the parties. In
such event, the parties shall use best efforts to negotiate, in good faith, a substitute, valid and enforceable provision or agreement which most nearly effects the parties’ intent in entering into this Agreement. 

12.5.    Third Parties. Nothing in this Agreement, express or implied, is intended to confer upon any person, other
than the parties hereto and their permitted successors and assigns any rights or remedies under or by reason of this Agreement. 

12.6.    Successors and Assigns. Subject to the provisions of Section 5.1, the provisions
of this Agreement shall inure to the benefit of, and shall be binding upon, the successors, permitted assigns, heirs, executors and administrators of the Parties hereto whose rights or obligations hereunder are affected by such provisions.
Notwithstanding anything contrary in this Agreement, this Agreement and the rights and obligations herein may be assigned or transferred by any Investors to any of its Affiliates; provided that in each case the transferee will agree by executing a
Deed of Adherence in the form attached hereto as Exhibit B to be subject to the terms of this Agreement to the same extent as if it were an original Investor hereunder. “Person” shall mean any individual, corporation,
partnership, limited partnership, proprietorship, association, limited liability company, firm, trust, estate or other enterprise or entity. “Control” shall mean the power or authority, whether exercised or not, to direct the
business, management and policies of a Person, directly or indirectly, whether through the ownership of voting securities, by contract or otherwise; provided, that such power or authority shall conclusively be presumed to exist upon possession of
beneficial ownership or power to direct the vote of more than fifty percent (50%) of the votes entitled to be cast at a meeting of the members or shareholders of such Person or power to control the composition of a majority of the board of directors
of such Person. The terms “Controlled” and “Controlling” have meanings correlative to the foregoing. Notwithstanding anything to the contrary contained herein, no Investor shall be deemed to be an Affiliate (or
Controlled Affiliate) of any Group Company and the Group Companies shall not be deemed to be an Affiliate (or Controlled Affiliate) of any Investor. 

12.7.    Interpretation; Captions. This Agreement shall be construed according to its fair language. The rule of
construction to the effect that ambiguities are to be resolved against the drafting party shall not be employed in interpreting this Agreement. The captions to sections of this Agreement have been inserted for identification and reference purposes
only and shall not be used to construe or interpret this Agreement. Unless otherwise expressly provided herein, all references to Sections and Exhibits herein are to Sections and Exhibits of this Agreement. 

  
 34 

 12.8.    Counterparts. This Agreement may be executed in one or
more counterparts and may be delivered by electronic or facsimile transmission, all of which shall be considered one and the same agreement and each of which shall be deemed an original. 

12.9.    Adjustments for Share Splits, Etc. Wherever in this Agreement there is a reference to a specific number of
shares of Series A Preferred Shares or Ordinary Shares of the Company, then, upon the occurrence of any subdivision, combination or share dividend of the Series A Preferred Shares or Ordinary Shares, the specific number of shares so referenced in
this Agreement shall automatically be proportionally adjusted to reflect the effect on the outstanding shares of such class or series of shares by such subdivision, combination or share dividend. 

12.10.    Aggregation of Shares. All Series A Preferred Shares or Ordinary Shares held or acquired by Affiliated
entities or persons (as defined in Rule 144 under the Securities Act) shall be aggregated together for the purpose of determining the availability of any rights under this Agreement. 

12.11.    Shareholders Agreement to Control. If and to the extent that there are inconsistencies between the
provisions of this Agreement and those of the Restated Articles, the terms of this Agreement shall prevail between the parties to this Agreement other than the Company. The parties other than the Company agree to take all actions necessary or
advisable, as promptly as practicable after the discovery of such inconsistency, to amend the Restated Articles so as to eliminate such inconsistency. 

12.12.    Dispute Resolution. 

(a)    Negotiation between Parties. The Parties agree to negotiate in good faith to resolve any dispute,
controversy, difference or claim arising out of or relating to this Agreement, including the existence, validity, interpretation, performance, breach or termination thereof between them regarding this Agreement. If the negotiations do not resolve
the dispute to the reasonable satisfaction of all Parties in dispute within thirty (30) days after one party delivers notice of dispute to the others, Section 12.12(b) shall apply. 

(b)    Arbitration. In the event the Parties in dispute are unable to settle a dispute between them regarding this
Agreement in accordance with subsection (i) above, such dispute shall be referred to and finally resolved by arbitration at the Hong Kong International Arbitration Centre (the “HKIAC”) for arbitration in Hong Kong. The
arbitration shall be conducted in accordance with the HKIAC Administered Arbitration Rules in force at the time of the initiation of the arbitration, which rules are deemed to be incorporated by reference into this subsection (ii). There shall be
three (3) arbitrators. Each Party or group of Parties in dispute shall be entitled to nominate one (1) arbitrator with the third arbitrator jointly nominated by the disputing Parties within thirty (30) days after the initiation of the
arbitration. Each of the arbitrators so nominated shall be qualified to practice the laws of Hong Kong. In the event that the disputing Parties cannot jointly agree on the third arbitrator within such thirty (30) day period, the HKIAC shall appoint
such arbitrator. The arbitral proceedings shall be conducted in English. The award of the arbitral tribunal shall be final and binding upon the Parties thereto. 

  
 35 

 12.13.    Further Actions. Each Shareholder of the Company agrees
that it shall use its best effort to enhance and increase the value and principal business of the Group Companies. 

12.14.    Waiver. The Company acknowledges that the Investors will likely have, from time to time, information that
may be of interest to the Company or its Subsidiaries (“Information”) regarding a wide variety of matters including (i) the technologies, plans and services, and plans and strategies relating thereto of such Investor,
(ii) current and future investments such Investor has made, may make, may consider or may become aware of with respect to other companies and other technologies, products and services, including technologies, products and services that may be
competitive with those of the Company or any of its Subsidiaries, and (iii) developments with respect to the technologies, products and services, and plans and strategies relating thereto, of other companies, including companies that may be
competitive with the Company or any of its Subsidiaries. The Company recognizes that a portion of such Information may be of interest to the Company or any of its Subsidiaries. Such Information may or may not be known by the Investors or the Series
A Directors. The Company, as a material part of the consideration for this Agreement, agrees that the Investors or the Series A Directors shall not have any duty to disclose any Information to the Company or any of its Subsidiaries, or permit the
Company or any of its Subsidiaries to participate in any projects or investments based on any such Information, or otherwise to take advantage of any opportunity that may be of interest to the Company or any of its Subsidiaries if it were aware of
such Information, and hereby waives, to the extent permitted by law, any claim based on the corporate opportunity doctrine or otherwise that could limit the Investor’s ability to pursue opportunities based on such Information or that would
require the Investors, the Series A Directors or their representative(s), to disclose any such Information to the Company or any of its Subsidiaries or offer any opportunity relating thereto to the Company or any of its Subsidiaries. 

12.15.    Additional Investors. Notwithstanding anything to the contrary contained herein, if the Company issues
additional Series A Preferred Shares after the date hereof pursuant to the Share Purchase Agreement, as such agreement may be amended from time to time in accordance with its terms, any purchaser of such Series A Preferred Shares may become a party
to this Agreement by executing and delivering to the Company an additional counterpart signature page to this Agreement and thereafter shall be deemed an “Investor” for all purposes hereunder. 

— REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK — 

  
 36 

 IN WITNESS WHEREOF, the parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	COMPANY:
	
	VISEN Pharmaceuticals
		
	By:	 	/s/ Shan Fu
		 	Name: Shan Fu
		 	Title: Director

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 

 IN WITNESS WHEREOF, the parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	 INVESTORS:

	
	 ASCENDIS PHARMA A/S

		
	By:	 	/s/ Michael Wolff Jensen, /s/ Jan Mikkelsen
	Name: Michael Wolff Jensen/Jan Mikkelsen
	Title: Chairman/CEO
	Address: Tuborg Boulevard 12, DK-2900, Hellerup

  

			
	ASCENDIS PHARMA ENDOCRINOLOGY DIVISION A/S
		
	By:	 	/s/ Michael Wolff Jensen, /s/ Jan Mikkelsen
	Name: Michael Wolff Jensen/Jan Mikkelsen
	Title: Chairman/CEO
	Address: Tuborg Boulevard 12, DK-2900, Hellerup

  

			
	ASCENDIS PHARMA BONE DISEASES A/S
		
	By:	 	/s/ Michael Wolff Jensen, /s/ Jan Mikkelsen
	Name: Michael Wolff Jensen/Jan Mikkelsen
	Title: Chairman/CEO
	Address: Tuborg Boulevard 12, DK-2900, Hellerup

  

			
	ASCENDIS PHARMA GROWTH DISORDERS A/S
		
	By:	 	/s/ Michael Wolff Jensen, /s/ Jan Mikkelsen
	Name: Michael Wolff Jensen/Jan Mikkelsen
	Title: Chairman/CEO
	Address: Tuborg Boulevard 12, DK-2900, Hellerup

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	INVESTORS:
	
	VIVO PLENILUNE IX LIMITED
		
	By: 	 	/s/ Albert Cha
	Name: 	 	Albert Cha
	Title: 	 	Director
	Address:	 	 505 Hamilton Avenue, Suite 207, Palo
 Alto,
CA 94301

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 IN WITNESS WHEREOF, the parties have caused their respective duly authorized representatives
to execute this Agreement as of the date and year first above written. 
  

			
	Sofinnova Venture Partners IX, L.P.
		
	By:	 	 Sofinnova Management IX, L.L.C.
 its General
Partner

		
	By	 	/s/ James Healy
		 	James Healy, Managing Member

 SIGNATURE PAGE OF SHAREHOLDERS AGREEMENT 

 EXHIBIT A 

PARTIES 
 Part I
    Investors 
  

			
	 Name of Investors
	  	 Number of Series A
Preferred
Shares

	 Ascendis Pharma Endocrinology Division A/S
	  	[***]
	 Ascendis Pharma Bone Diseases A/S
	  	[***]
	 Ascendis Pharma Growth Disorders A/S (together with Ascendis Pharma Endocrinology Division A/S and
Ascendis Pharma Bone Diseases A/S, “Ascendis”)
	  	[***]
	 Vivo Plenilune IX Limited (“Vivo Capital”)
	  	[***]
	 Sofinnova Venture Partners IV, L.P. (“Sofinnova”)
	  	[***]
	 Total
	  	[***]

 Part III     Notice Address 

For the purpose of the notice provisions contained in this Agreement, the following are the initial addresses of each Party: 

If to the Company: 
 Address: International Corporation
Services Ltd., P.O. Box 472, Harbour Place, 2nd Floor, 103 South Church Street, George Town, Grand Cayman KY1-1106, Cayman Islands 

With a copy to: 
 Vivo Capital 

Address: 505 Hamilton Avenue, Suite 207, Palo Alto, CA 94301 

Tel: (650) 688-0818 

Attention: Albert Cha 

E-mail address: acha@vivocapital.com 

and 
 Ascendis 

EXHIBIT A 

 Address: Tuborg Boulevard 12 

2900 Hellerup 
 Denmark 

Tel: +45 70 22 22 44 
 Attention: Michael Wolff Jensen 

E-mail address: mwj@ascendispharma.com 

If to Ascendis 
 Tuborg Boulevard 12 

2900 Hellerup 
 Denmark 

Attention: Michael Wolff Jensen 

E-mail address: mwj@ascendispharma.com 

If to Vivo Capital 
 Tel: (650) 688-0818 
 Attention: Albert Cha 

E-mail address: acha@vivocapital.com 

If to Sofinnova 
 3000 Sand Hill Road, Bldg. 4, Suite 250

 Menlo Park, CA 94025 
 EXHIBIT A 

 EXHIBIT B 

FORM OF DEED OF ADHERENCE 
  

			
	 To:
	  	VISEN Pharmaceuticals
		  	 Parties to the Shareholders Agreement (as defined
below)

			
		
	 From:
	  	                                     
   
		
	 Date:    
	  	                                     
   

 Dear Sirs, 

Deed of Adherence 

The undersigned hereby agree and covenant with each of you pursuant to this Deed of Adherence that the undersigned will abide by all the
provisions of the Shareholders Agreement entered into by and among the Company and each of the parties named therein, dated as of [DATE], 2018, as amended from time to time (the “Shareholders Agreement”), as the Investors under the
terms of the Shareholders Agreement and a party to the Shareholders Agreement. 
  

	
	 [_________________]

	
	
By:                  
                                         
  

	 Name:

	 Title:

	
	 Address:

 EXHIBIT BEX-4.15

 Exhibit 4.15 

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such
excluded information is not material and would likely cause competitive harm to the registrant if publicly disclosed. 
 EXECUTION VERSION 

CONFIDENTIAL 
 Exclusive Licence Agreement

 between 
 Ascendis Pharma Growth
Disorders A/S 
 as the Licensor or Ascendis on the one hand 

and 
 VISEN PHARMACEUTICALS 

as the Licensee on the other hand 

 CONTENTS 
  

							
			
	1.	  	Interpretation	  	 	1	 
			
	2.	  	Grants and Restrictions	  	 	8	 
			
	3.	  	Technical Information and Patents	  	 	10	 
			
	4.	  	Development and Commercialisation	  	 	11	 
			
	5.	  	Manufacturing	  	 	13	 
			
	6.	  	Regulatory	  	 	13	 
			
	7.	  	Payments	  	 	14	 
			
	8.	  	Records and Auditing	  	 	15	 
			
	9.	  	Pharmacovigilance	  	 	15	 
			
	10.	  	Confidentiality	  	 	15	 
			
	11.	  	Intellectual Property	  	 	17	 
			
	12.	  	Prosecution, Maintenance and Defence	  	 	18	 
			
	13.	  	Enforcement of Patent Rights and Defence of Third Party Claims	  	 	20	 
			
	14.	  	Warranties	  	 	21	 
			
	15.	  	Indemnification	  	 	22	 
			
	16.	  	Limitation of Liability	  	 	23	 
			
	17.	  	Term and Survival	  	 	24	 
			
	18.	  	Termination	  	 	24	 
			
	19.	  	Effect of Termination	  	 	25	 
			
	20.	  	Dispute Resolution	  	 	27	 
			
	21.	  	Miscellaneous	  	 	29	 
		
	SCHEDULE 1 : Patents	  			
		
	SCHEDULE 2 : Technical Information	  			
		
	SCHEDULE 3 : EXCLUDED INDICATIONS	  			
		
	SCHEDULE 4 : Short Form Patent Licence	  			

  

  
 i 

 THIS EXCLUSIVE LICENCE AGREEMENT (the “Agreement”) is dated November 7,
2018 and made 
 BETWEEN: 
  

	(1)	 ASCENDIS PHARMA GROWTH DISORDERS A/S, (“Licensor” or
“Ascendis”), a company registered in Denmark with its registered office at Tuborg Boulevard 5, DK-2900 Hellerup, Denmark; 

 

	(2)	 VISEN PHARMACEUTICALS, (“Licensee”), a company established under the laws of the Cayman
Islands with its registered address at P.O. Box 472, 2nd Floor, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1106, Cayman Islands. 

Ascendis and the Licensee are each a “Party”, and together the “Parties”, to this Agreement. 

Background: 
  

	(A)	 Ascendis and its Affiliates Control proprietary rights, titles and interests in patents and technical
information relating to Licensed Products (as defined below) within the area of growth disorders. 

  

	(B)	 The Licensee wishes to develop and to commercialise such Licensed Products in the Field in the Territory (such
terms defined below), and Ascendis wishes to grant the Licensee an exclusive licence under certain patents, technical information and other intellectual property to develop and commercialise such Licensed Products in the Field in the Territory, on
the terms and conditions of this Agreement. 

 THE PARTIES AGREE THAT: 

 

	1.	 Interpretation 

 

	1.1	 Definitions 

“Accounting Standard” means, with respect to the Licensee, either: (a) International Financial Reporting Standards
(“IFRS”); or (b) United States generally accepted accounting principles (“GAAP”), in either case, which standards or principles (as applicable) are currently used at the applicable time, and as consistently
applied, by the Licensee. 
 “Affiliate” means any business Entity which from time-to-time controls, is controlled by or is under common control with a Party to this Agreement, in each case only for so long as such control exists. As used in this definition, “control” of an
Entity means the beneficial ownership (either directly or indirectly) of more than fifty percent (50%) of the total voting power of the shares or securities then outstanding normally entitled to vote in elections of the board of directors or other
managing authority of such Entity. For the avoidance of doubt, neither Licensee nor any of its subsidiaries shall be considered as an Affiliate of Ascendis and an Affiliate of Ascendis shall not be considered as an Affiliate of either Licensee or
its subsidiaries for the purposes of this Agreement. 
 “Applicable Laws” means all laws, statutes, codes, ordinances, rules and
regulations that have been enacted (including without limitation by a Regulatory Authority) in any jurisdiction in the Territory and which are in force as of the Effective Date or come into force during the term of this Agreement and that are
applicable to the research, development, Manufacture, or commercialization of Licensed Product or the activities of the Parties under this Agreement, including, without limitation: (a) applicable regulations and guidelines of the NMPA and other
Regulatory Authorities and the ICH guidelines; (b) applicable Good Clinical Practices, Good Laboratory Practices and Good Manufacturing Practices promulgated by the NMPA and other Regulatory Authorities or the ICH; and (c) all applicable
industry and trade standards, including the applicable standards of the ISO with, at a minimum, the ISO 9001/9002 quality standards. 

  
 1 

 “Ascendis FTE Costs” means, for all activities performed by Ascendis or its Affiliates in
accordance with the Research and Technical Development Plan or as otherwise directed in writing by the Licensee and agreed to by Ascendis or its Affiliates, the product of: (a) the number of FTEs used by Ascendis or its Affiliates for such
activities as set forth in a Research and Technical Development Plan or other written document approved by the Licensee; and (b) the Ascendis FTE Rate. For the avoidance of doubt, the costs of approved service providers fulfilling the
obligations of Ascendis or its Affiliates in performing such activities are covered separately under subsection (A) of the “Research and Technical Development Plan Expenses” definition, and are not a part of the Ascendis FTE Costs.

 “Ascendis FTE Rate” means (a) if, at the time the applicable Ascendis FTE Costs are incurred, Ascendis owns [***] percent ([***]%)
or more of all outstanding preferred shares of Licensee, [***] Euros (€ [***]) per FTE, and (b) if, at the time the applicable Ascendis FTE Costs are incurred, Ascendis owns less than [***] percent ([***]%) of outstanding preferred
shares of Licensee, [***] Euros (€ [***]) per FTE; provided in each case of (a) and (b), such amount is fully burdened and includes without limitation, for each FTE, [***], utilities, [***], and a pro rata allocation of general and
administrative expenses. 
 “Ascendis Program IP” means: any Program IP conceived or generated solely by employees, agents or service
providers of Ascendis or its Affiliates. 
 “Ascendis Indemnitee” has the meaning ascribed to it in Clause 15.1. 

“Ascendis Patents” means: (a) the patents and patent applications listed in Schedule 1 as of the Effective Date and any conversion,
continuation, continuation-in-part, division, provisional or substitution thereof, and any patents issuing thereon, any reissues,
re-examinations, confirmations or extensions of such patents (including supplementary protection certificates) and any foreign counterparts of such patent applications and patents in any country in the
Territory; and (b) any and all other Patents that are Controlled by Ascendis or its Affiliates as of the Effective Date or at any time thereafter during the term of this Agreement (including without limitation Patents within the Ascendis
Program IP or Joint Program IP) that are necessary or useful to make, have made, use, sell, offer for sale or import a Licensed Product. 

“Ascendis Technical Information” means: (a) the Technical Information listed in Schedule 2 as of the Effective Date; and (b) any
and all other Technical Information that is Controlled by Ascendis or its Affiliates, as of the Effective Date or at any time thereafter during the term of this Agreement (including without limitation Technical Information within the Ascendis
Program IP or Joint Program IP), that is necessary or useful to make, have made, use, sell, offer for sale or import a Licensed Product. 

“Ascendis Platform Technology” means, as of the Effective Date or at any time thereafter during the term of this Agreement, Ascendis’
proprietary chemistry, materials and methodologies for [***] a substrate of interest (e.g., [***]) to various carriers (including [***]) via a TransCon Linker, [***]. 

“Bankrupt Party” has the meaning ascribed to it in Clause 18.3(A). 

“Business Day” means a day (other than a Saturday or Sunday) on which banks are open for ordinary face to face banking business in Copenhagen
(Denmark), Cayman, China, and San Francisco (California, USA). 

  
 2 

 “Change of Control” means the occurrence of any of the following events: (a) any
Competitor takes control (as the term “control” is defined in the definition of “Affiliate”) of Licensee; or (b) Licensee: (i) consolidates with, or merges with or into, a Competitor; or (ii) transfers all or
substantially all of its assets to any Competitor. 
 “Competitor” means a Third Party that [***] commercializing (i.e., as the party
having the proprietary rights to and booking sales for, but not as a distributor or wholesaler of) a [***] in [***] as of the date of a Change of Control.  

“Confidential Information” means confidential Technical Information (of whatever kind and in whatever form or medium, including copies
thereof): (a) disclosed by or on behalf of a Party in connection with this Agreement, whether prior to or during the term of this Agreement and whether disclosed orally, electronically, by observation or in writing; and/or (b) created by, or on
behalf of, either Party, or created jointly by the Parties, in the course of this Agreement. “Confidential Information” includes confidential Technical Information regarding such Party’s research, development plans, clinical trial
designs, preclinical and clinical data, technology, products, business information or objectives and other information of the type that is customarily considered to be confidential information by Parties engaged in activities that are substantially
similar to the activities being engaged in by the Parties pursuant to this Agreement. The following shall be deemed the Confidential Information of the Licensee: any and all financial or product pipeline information related to the Licensee provided
to Ascendis (whether provided by the Licensee itself or through a Third Party), as well as Licensee Program IP, and the Research and Technical Development Plans. The following shall be deemed the Confidential Information of Ascendis: Ascendis
Platform Technology, Ascendis Technical Information, Ascendis Program IP and Ascendis Patents. The following shall be deemed the Confidential Information of both Parties: the terms and conditions of this Agreement. 

“Control” or “Controlled” means, with respect to an item of information or Intellectual Property, that a Party has the
right, power and legal authority, whether arising by ownership, licence or other authorisation, to disclose, and/or to grant and authorise licences or sub-licences under, such items as required under the terms
of this Agreement, without violating the terms of any written agreement with any Third Party under which such Party or its Affiliates first acquired such rights to such item of information or Intellectual Property. 

“Diligent Efforts” means with respect to a Party’s research, development, and commercialisation of Licensed Products, the level of
efforts and resources such Party would typically exert in similar circumstances pursuing the development and commercialisation of a similar product with similar market potential taking into account the stage of development or commercialisation,
market potential and market size, the product life cycle, the risk of development or commercialisation of the Licensed Product, the cost effectiveness of efforts or resources, the competitiveness of alternative products that are or are expected to
be in the marketplace, the scope and duration of patent rights or other proprietary rights related to the Licensed Product, and the profitability of the Licensed Product [***]. The efforts and resources of each Party’s respective Affiliates and
Sub-Licensees shall count towards that Party’s own Diligent Efforts. Notwithstanding the foregoing, the exercise of diligence by the Licensee shall be determined by judging the Licensee’s
commercially reasonable efforts taken as a whole [***]. 
 “Effective Date” means the date of this Agreement. 

“Endocrinology Disorders” means [***] 

“Endocrinology Product” means a product consisting of a substrate of interest (e.g., [***] to a carrier of interest (including
[***] via a TransCon Linker for the treatment of Endocrinology Disorders; provided, that [***] 

  
 3 

 “Entity” means, and includes, any person, firm or company or group of persons or
unincorporated body. 
 “Excluded Indications” means the indications specified in Schedule 3. 

“Executives” means the Chief Executive Officer at the Licensee and the Chief Executive Officer at Ascendis. 

“FDA” means the US Food and Drug Administration or any successor agency with comparable responsibilities. 

“Field” means the treatment and/or prevention of any disease, condition or disorder of any human indication, excluding the Excluded
Indications. 
 “Force Majeure” means any circumstances not within the reasonable control of the Party concerned including, without
limitation: (a) any strike, lockout or other industrial action, or any shortage of or difficulty in obtaining labour, fuel, raw materials or components; (b) any destruction, temporary or permanent breakdown, malfunction or damage of or to
any premises, plant, equipment (including computer systems) or materials; (c) any breach of contract, default or insolvency by or of any Third Party, other than an Affiliate of the Party affected by the force majeure, or an employee or officer
of that Party or Affiliate; (d) any action taken by a governmental or public authority imposing an embargo, export or import restriction, rationing, quota or other restriction or prohibition; (e) any civil commotion or disorder, riot,
invasion, war, threat of or preparation for war; or (f) any accident, fire, or explosion, (other than in each case, one caused by a breach of contract by or assistance of the Party concerned) storm, flood, earthquake, subsidence, epidemic or
other natural physical disaster. Notwithstanding the foregoing, lack of funds, manpower or equipment, interruption or failure of utility service and the fault or misconduct by any personnel engaged by a Party shall not be an event of Force Majeure.

 “FTE” means a full time equivalent person year of work (consisting of [***]), prorated on a daily or hourly basis as necessary. 

“Good Clinical Practice” means the applicable principles and guidelines for good clinical practice for drugs and medicinal products, as such
principles and guidelines are amended, implemented and supplemented from time-to-time, including without limitation those set out in the Harmonised Tripartite Guideline
for Good Clinical Practice as finalised by the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 

“Good Distribution Practice” means the applicable principles and guidelines for good distribution practice of drugs and medicinal products,
as such principles and guidelines are amended, implemented and supplemented from time-to-time, including without limitation those set out in Guidelines of
5 November 2013 on Good Distribution Practice of medicinal products for human use, based on Article 84 and Article 85b(3) of Directive 2001/83/EC. 

“Good Laboratory Practice” means the applicable principles and guidelines for good laboratory practice for drugs and medicinal products, as
such principles and guidelines are amended, implemented and supplemented from time-to-time, including without limitation those set out in the OECD Principles of Good
Laboratory Practice published by the Organisation for Economic Co-Operation and Development. 
 “Good
Manufacturing Practice” means all applicable principles and guidelines for good manufacturing practice for drugs and medicinal products, as such principles and guidelines are amended, implemented and supplemented from time-to-time, including without limitation as specified in the applicable provisions of (i) European Directive 2003/94/EC and further guidance as published by the
European Commission in Volume IV of “The rules governing medicinal products in the European Community” and (ii) Title 21 Parts 210 and 211 of the US Code of Federal Regulations (21 CFR, parts 210 and 211). 

  
 4 

 “ICH” means the International Conference on Harmonisation of Technical Requirements for
Registration of Pharmaceuticals for Human Use. 
 “Indemnified Party” has the meaning ascribed to it in Clause 15.3. 

“Injector” means any device developed by Ascendis for the purpose of administering TransCon CNP. 

“Intellectual Property” means registered or unregistered trademarks, Patents, registered designs, unregistered design rights, business,
company, domain or product names, service marks, copyright, know-how, Confidential Information, database rights, any rights in clinical study results, applications for and the right to apply for any of the
foregoing, and any similar or analogous rights anywhere in the Territory. 
 “Intellectual Property Office” means the official local
patent, trade mark or other Intellectual Property registry in each part of the Territory responsible for granting, maintaining records of, Patents, trademarks or other Intellectual Property and any instruments made in respect thereof. 

“ISO” means the International Organization for Standardization. 

“Joint Development Committee” or “JDC” means the joint development committee established under Clause 4.6. 

“Joint Program IP” means any Program IP conceived or generated during the course of, and in connection with, this Agreement by
employees, agents or service providers of both Ascendis and the Licensee or their respective Affiliates or Sub-Licensees. 

“Licensed Product” means a product consisting of C-type natriuretic peptide (CNP) [***] to a carrier
[***] by a TransCon Linker and which is developed utilizing the Ascendis Platform Technology, regardless of its finished form, formulation or dosage, alone (the foregoing alone, “TransCon CNP”) and, if Ascendis has developed an Injector
for use in a clinical trial outside the Territory, also including the Injector. 
 “Licensed Product Patents” means all Ascendis Patents
that claim [***] a Licensed Product in the form as which is concurrently being developed or commercialised, as applicable, by or on behalf of Ascendis or its Affiliates outside of the Territory.  

“Licensee Program IP” means: any Program IP conceived or generated solely by employees, agents or service providers of the Licensee or its
Affiliates. 
 “Licensee Indemnitee” has the meaning ascribed to it in Clause 15.2. 

“Long-Acting Product” is a product that is intended to be administered to a subject once a week or less frequently than once a week. 

“Loss” or “Losses” means any and all losses, liabilities, damages, fines, penalties, costs or expense (including reasonable
attorneys’ fees and other expenses of litigation). 
 “Manufacture” or “Manufacturing” means any manufacturing
activity of any Licensed Product, or any ingredient thereof, including manufacturing for pre-clinical or clinical use, or commercial sale, testing, handling, packaging and storage, ongoing stability tests and
regulatory activities related to any of the foregoing. 

  
 5 

 “NMPA” means the National Medical Product Administrations of the People’s Republic of
China, or any successor agency with comparable responsibilities. 
 “Non-Bankrupt Party” has the
meaning ascribed to it in Clause 18.3(A). 
 “Patents” means any and all: (a) issued patents, including inventor’s certificates;
(b) patent applications, including any conversion, continuation, continuation-in-part, division, provisional or substitution thereof, and any patents issuing
thereon; (c) any reissues, re-examinations, confirmations or extensions of such patents (including supplementary protection certificates); and (d) any foreign counterparts of such patent applications
and patents in any country in the Territory. 
 “Program IP” means any data, results (including all clinical data), improvements and
inventions generated by or on behalf of Ascendis or Licensee, or the Parties jointly, in connection with the research, development, Manufacturing, or commercialization activities conducted with respect to the Licensed Product under this Agreement,
and all Intellectual Property therein. 
 “Quarterly Period” means each period of three months commencing on 01 January, 01 April, 01 July
and 01 October in a given calendar year. 
 “Regulatory Approval” means any and all approvals, licenses, registrations, or authorizations
of any country, federal, supranational, state, or local regulatory agency, department, bureau, or other government entity that are necessary for the commercialisation of any Licensed Product in a given jurisdiction. 

“Regulatory Authority” means any national, supra-national, regional, state or local regulatory agency, department, bureau, commission,
council or other governmental entity in any jurisdiction in the Territory involved in the granting of Regulatory Approval for, or involved in the regulation of, pharmaceutical products. 

“Research and Technical Development Plan” has the meaning ascribed to it in Clause 4.1. 

“Research and Technical Development Plan Activities” means the Research and Technical Development Plan Activities allocated to Ascendis or
its Affiliates as set forth in a Research and Technical Development Plan. 
 “Research and Technical Development Plan Expenses” means the
following costs and expenses actually incurred by Ascendis or its Affiliates after the Effective Date in carrying out the Ascendis Research and Technical Development Plan Activities: 

 

	 	(A)	 the out-of-pocket costs
incurred by Ascendis or its Affiliates of having the Research and Technical Development Plan Activities performed by approved service providers (including without limitation Third Party manufacturing organisations) in accordance with the applicable
Research and Technical Development Plan; 

  

	 	(B)	 Ascendis FTE Costs; and 

 

	 	(C)	 any other costs or expenses specifically identified and included in the applicable Research and Technical
Development Plan, which, for the avoidance of doubt, may include, without limitation, pre-paid amounts. 

  
 6 

 “Share Purchase Agreement” shall mean that certain Share Purchase Agreement dated as of
even date herewith, by and among Licensee, Ascendis-China Ltd., Ascendis Pharma A/S, Vivo Plenilune IX Limited, and Sofinnova Venture Partners IX, L.P. 

“Shareholders Agreement” means that certain Shareholders Agreement dated as of even date herewith, by and among Licensee, Ascendis-China Ltd.,
Ascendis Pharma A/S, Vivo Plenilune IX Limited, and Sofinnova Venture Partners IX, L.P. 
 “SDEA” has the meaning ascribed to it in Clause
9.1. 
 “Sub-Licensee” means any Entity that has been granted a
sub-licence by either Party of its rights granted hereunder in accordance with Clause 2.4. 
 “Technical
Information” means any and all: (a) identifiable know-how, data, inventions, discoveries, findings, methods, proprietary information, processes, techniques, materials and other information and
technology (whether patentable or not) including formulae, biological materials, practices, test data (including pharmacological, toxicological and clinical information and related reports, statistical analyses, expert opinions and the like),
analytical and quality control data, marketing, pricing, distribution, cost and sales data or descriptions; and (b) all Intellectual Property with respect to the items in subsection (a) above other than Patents. For clarity, as used in
this Agreement, the term “Technical Information” excludes Patents. 
 “Territory” means the People’s Republic of China,
including Hong Kong, Macao and Taiwan. 
 “Third Party” means any Entity other than Ascendis or its Affiliates or its Sub-Licensees, or the Licensee or its Affiliates or its Sub-Licensees. 

“Third Party Claim” means any action, suit or other proceedings brought by a Third Party. 

“TransCon Hydrogel” means Ascendis’ proprietary [***] hydrogel containing TransCon Linkers 

“TransCon Linker” means Ascendis’ proprietary linker used in [***] a substrate of interest to various carriers (including [***], which
chemical linker [***]. 
 “TransCon [***]” means Ascendis’ proprietary [***]-based carrier containing TransCon Linkers. 

“Valid Claim” means any claim of a Patent that has not expired or been disclaimed, abandoned or dedicated to the public, or held revoked,
unenforceable, unpatentable or invalid (whether through reexamination, reissue, opposition or otherwise) by a decision of a court or governmental agency of competent jurisdiction, which decision is unappealable or unappealed within the time frame
allowed for appeal. 
 “VAT” means value added tax as provided for in the Value Added Tax Act 1994 and legislation supplemental thereto,
TVA or any other system of value added tax as provided for in Council Directive 2006/112/EC applied in any Member State of the European Union and any other similar turnover, sales or purchase, tax or duty levied by any other jurisdiction whether
central, regional or local. 
  

	1.2	 Construction 

In this Agreement where the context admits: 
  

	 	(A)	 references to any statute or statutory provisions shall be deemed to refer to those provisions as amended or re-enacted or as their application is modified by other provisions from time-to-time and any reference to a statutory provision shall
include any subordinate legislation made from time-to-time under that provision; 

  
 7 

	 	(B)	 references to “this Agreement” or to any other agreement or document referred to in this Agreement
mean this Agreement or such other agreement or document as may be amended, varied, supplemented, modified or novated from time-to-time, and include the Schedules;

  

	 	(C)	 references to Clause(s) and Schedule(s) are references to clause(s) and schedule(s) of and to this Agreement,
and each of the Schedules shall have effect as if set out in this Agreement; 

  

	 	(D)	 references to “proprietary” mean Controlled by a Party, but do not infer any requirement of a Patent;

  

	 	(E)	 the headings and sub-headings in this Agreement are inserted for
convenience only and shall not affect the construction of this Agreement; 

  

	 	(F)	 the singular includes the plural and vice versa, and references to the masculine, feminine and the neuter shall
include all such genders; 

  

	 	(G)	 references to any Party include its successors and permitted assigns; 

 

	 	(H)	 the symbol “€” means the lawful currency of the member states of the European Union that adopt
the single currency in accordance with the EC Treaty, known as the “Euro”; and 

  

	 	(I)	 the symbol “$” means the lawful currency of the United States of America, known as the “US
Dollar”. 

  

	2.	 Grants and Restrictions 

 

	2.1	 Ascendis hereby grants to the Licensee an exclusive (even as to Ascendis, and subject to the terms and
conditions of this Agreement), royalty-free (in accordance with Clause 7) licence (with the right to grant sub-licences subject to Clause 2.4) under Ascendis Patents and Ascendis Technical Information to
develop, Manufacture, have made, use, sell, offer for sale, import, export or otherwise commercialize Licensed Product in the Field in the Territory. Licensee has the right to grant sublicenses (through one or more tiers) to its Affiliates that are
operating companies for China, Hong Kong or other regions in the Territory and such sublicense agreements will be entered into each within [***] ([***]) days after the applicable operating company is incorporated and becomes operational (each such
applicable operating company, a “Sublicensed Affiliate”). 

  

	2.2	 The Licensee hereby grants to Ascendis a non-exclusive, royalty-free,
fully-paid, perpetual, irrevocable license (with the right to grant sub-licences subject to Clause 2.4) under the Licensee Program IP and Licensee’s and its Affiliates’ interest in Joint Program IP,
in each case that are Controlled by the Licensee or its Affiliates, to make, have made, use, sell, offer for sale or import Licensed Products in any field of use outside the Territory. Ascendis will have the right to convert such non-exclusive license (in whole or in part, at Ascendis’s discretion) to an exclusive license on commercial reasonable terms to be negotiated between the Parties in good faith. 

  
 8 

	2.3	 Restrictions 

  

	 	(A)	 During the term of this Agreement, neither Ascendis nor its Affiliates shall conduct, or intentionally enable,
or participate in, or license or otherwise authorize any Third Party to conduct, enable or participate in, the research, development, Manufacture or commercialisation of any Competing Product in the Territory (whether for its own account or for any
Third Party). As used in this Clause 2.4, a “Competing Product” shall mean [***]. 

  

	 	(B)	 During the term of this Agreement, the Licensee covenants that it shall not, and Licensee shall procure that
its Affiliates and Sub-Licensees shall not, use or exploit the Ascendis Patents or Ascendis Technical Information otherwise than as expressly permitted under the licences granted to Licensee in Clause 2.1.
Further, the Licensee shall not grant any license to any Third Party to Licensee’s and its Affiliates interest in (i) Program IP [***] and (ii) any Program IP solely relating to the Ascendis Platform Technology [***], in each case of
(i) and (ii), without the prior written consent of Ascendis. 

  

	2.4	 Each Party agrees that: 

 

	 	(A)	 any and all sub-licences granted under Clauses 2.1 and 2.2 shall be on
terms consistent with the terms of this Agreement, contain obligations on each Sub-Licensee to perform and observe terms and conditions similar to those contained herein so far as the same are applicable;

  

	 	(B)	 it shall be liable to the other Party for any acts and omissions of its
Sub-Licensee that cause any breach of the provisions of this Agreement; and 

  

	 	(C)	 it shall, within [***] ([***]) days of the grant of each sub-licence,
provide the other Party with [***], provided that [***] from such sub-licence: [***]. 

  

	2.5	 Ascendis shall [***] not to commit any acts or omissions that could cause a material breach of any licence
agreement pursuant to which Ascendis has rights to Intellectual Property that it has sub-licensed to the Licensee under this Agreement, such that its Third Party licensor terminates or amends such licence
agreement in any way that materially adversely affects a licence or other right granted to the Licensee under this Agreement that is used in a Licensed Product being developed (including under an active Research and Technical Development Plan) or
commercialised by the Licensee. Ascendis shall not exercise any rights it may have with respect to any such licence agreement, or amend, terminate, or waive any of its rights under such licence agreement in any way that materially adversely affects
a licence or other right granted to the Licensee under this Agreement that is used in a Licensed Product being developed (including under an active Research and Technical Development Plan) or commercialised by the Licensee. 

 

	2.6	 Only the licences granted or retained pursuant to the express terms of this Agreement shall be of any legal
force or effect. No other licence rights shall be created by implication, estoppel or otherwise under this Agreement. 

  

	2.7	 Each Party shall procure that its Affiliates shall comply with the terms and conditions of this Agreement and
shall be liable to the other Party for any acts or omissions of such Affiliates which are not in compliance with the terms and conditions of this Agreement. 

  
 9 

	2.8	 During the term of this Agreement, prior to engaging in substantive discussions with a Third Party regarding
the license to such Third Party by Ascendis or its Affiliates under the Ascendis Platform Technology of [***] commercialise Endocrinology Product(s) in the Territory, either by license, option, or otherwise (a “ROFN
Opportunity”), Ascendis shall notify Licensee thereof, except to the extent Ascendis cannot grant to Licensee or its Affiliates any rights to such Endocrinology Products in the Territory in light of restrictions imposed on Ascendis or
its Affiliates under agreements by and between Ascendis or its Affiliates (on the one hand) and a Third Party (on the other hand) existing as of the “Initial Closing Date” (as such term is defined in the Share Purchase Agreement. No later
than [***] ([***]) Business Days after Licensee’s receipt of such notice, Licensee shall notify Ascendis whether Licensee wishes to enter into negotiations with Ascendis to negotiate an agreement for Licensee to obtain the right corresponding
to such ROFN Opportunity on reasonable commercial terms to be agreed on in good faith (“ROFN License Agreement”). If Licensee does not timely notify Ascendis that it wishes to negotiate for the ROFN Opportunity, or notifies Ascendis that
it is not interested in the ROFN Opportunity, Ascendis shall be free to engage with Third Parties discussions of such ROFN Opportunity, and Licensee shall have no further rights under this Clause 2.8 with respect to such ROFN Opportunity. If
Licensee timely notifies Ascendis it wishes to negotiate an agreement for such ROFN Opportunity, the Parties shall enter into good faith negotiations not to exceed [***] ([***]) days with the goal of finalizing the terms of and executing such ROFN
License Agreement. If after the expiration of such [***] ([***])-day period (the “ROFN Negotiation Stop Date”), the Parties have not executed such ROFN License Agreement, Ascendis shall be free to engage with Third Parties discussions of
such ROFN Opportunity [***], and Licensee shall have no further rights under this Clause 2.8 with respect to such ROFN Opportunity. Notwithstanding any other provision of this Clause 2.8, in no event shall this Clause 2.8 limit in any way the
ability of Ascendis or its Affiliates to engage in discussions with a Third Party for [***] to such Third Party under the Ascendis Platform Technology to [***] commercialise an Endocrinology Product so long as such discussions are not in conflict
with Ascendis’s obligations under Clause 2.3(A), and any such discussions shall not be deemed a “ROFN Opportunity” for which this Clause 2.8 applies. 

 

	2.9	 In the event that Ascendis discontinues the development or commercialization of Licensed Product outside the
Territory, or if Licensee discontinues the development or commercialization of Licensed Product in the Territory for safety, efficacy and/or regulatory reasons relating to Licensed Product (a “Qualifying Discontinuance”), Ascendis or
Licensee, as the case may be, shall promptly inform the other Party of such Qualifying Discontinuance and shall provide relevant data and documentation which forms the basis of such decision to the other Party. In the event of a Qualifying
Discontinuance, upon the Licensee’s request, Ascendis shall provide to the Licensee [***] for its other Endocrinology Products which are [***] and for which Ascendis has not granted any Third Party [***] in the Territory, and the Licensee may
elect to (i) continue activities with respect to the relevant Licensed Product in the Territory, or (ii) substitute the relevant Licensed Product with one of such other Endocrinology Products, [***], in which event such Endocrinology
Product will become a Licensed Product and the Parties shall execute an amendment to this Agreement to memorialize the same. Further, if Licensee requires any technology transfer in connection with such substitution under clause (ii) of the
preceding sentence, the Parties [***] the scope and timing for such transfer, as well as FTE-based payments to be made to Ascendis with respect to such transfer activities. 

 

	3.	 Technical Information and Patents 

 

	3.1	 Within [***] ([***]) days of the Effective Date, Ascendis shall deliver and provide to the Licensee the items
of Ascendis Technical Information listed in Schedule 2. 

  
 10 

	3.2	 Ascendis shall use its Diligent Efforts to provide the Licensee with any additional Technical Information that
is not specified in Schedule 2 but is Controlled by Ascendis and/or its Affiliates relating to the Ascendis Technical Information or Ascendis Platform Technology during the term of this Agreement that is necessary or useful for the Licensee to make,
have made, use, sell, offer for sale or import Licensed Product in the Field in the Territory. [***]. 

  

	3.3	 Upon the Licensee’s written request, but in no event more than [***] during the term of this Agreement,
Ascendis shall provide, [***] to the Licensee a written update (as of the date the request is received by Ascendis) of the Licensed Product Patents in Schedule 1 and/or Ascendis Technical Information in Schedule 2. 

 

	4.	 Development and Commercialisation 

 

	4.1	 Within [***] days following the Effective Date, the Parties shall agree to a research and technical development
plan (the “Research and Technical Development Plan”) that sets forth the Parties’ respective Research and Technical Development Plan Activities, which may be amended from time to time by the JDC in accordance with this
Agreement. The Parties shall perform and complete, or cause the performance and completion of, their respective Research and Technical Development Plan Activities, and deliver to each other a summary of the results (including raw data if reasonably
requested by a Party), samples and reports arising therefrom in accordance with each Research and Technical Development Plan within [***] ([***]) days following completion thereof. 

 

	4.2	 The Licensee shall provide Ascendis with a draft of each Research and Technical Development Plan. The Licensee
shall consider, in good faith, any comments regarding each draft Research and Technical Development Plan that Ascendis provides to the Licensee within [***] ([***]) days of Ascendis’ receipt of such draft Research and Technical Development
Plan. In addition, the Licensee shall keep Ascendis informed of the progress of the development of each Licensed Product against the applicable Research and Technical Development Plan at each meeting of the JDC pursuant to Clause 4.6(A).

  

	4.3	 The Licensee shall be solely responsible for any clinical trial activities carried out as part of its
development and commercialisation activities in the Territory. 

  

	4.4	 The Licensee shall use Diligent Efforts to develop and commercialise Licensed Product in the Field in the
Territory. 

  

	4.5	 Each Party shall conduct all development of Licensed Product in compliance with current Good Laboratory
Practice, Good Clinical Practice and Good Manufacturing Practice, in each case, where applicable. Neither Party shall use any person that has been debarred, disqualified or banned from practising medicine to perform activities under this Agreement,
and each Party shall immediately notify the other Party in writing if any person performing activities under this Agreement is disqualified, debarred or banned from practising medicine. 

 

	4.6	 Joint Development Committee 

 

	 	(A)	 Formation of JDC 

Promptly after the Effective Date, the Parties will form a Joint Development Committee comprised of three (3) representatives of Ascendis
and three (3) representatives of the Licensee for the first Research and Technical Development Plan (and will promptly form a JDC following agreement between the Parties in relation to each additional Research and Technical Development Plan).
Ascendis agrees that it shall not have the right to nominate representatives of the Licensee to the JDC notwithstanding its ownership in the Licensee. 

  
 11 

 One representative of the Licensee at the JDC will be selected to act as the chairperson of
the JDC. The JDC will meet at least [***] ([***]) times per year during the term of a Research and Technical Development Plan. Such meetings may be conducted by videoconference, teleconference or in person, as agreed by the Parties. The JDC will
agree upon the time and location of the meetings. The chairperson, or his or her designee, will circulate an agenda for each meeting approximately [***] before the date scheduled for the meeting, and will include all matters requested to be included
on such agenda by either Party. The chairperson, or his or her designee, will take complete and accurate minutes of all discussions occurring at the JDC meetings and all matters decided upon at the meetings except that matters reflecting legal
advice of counsel will not be included in such minutes. A copy of the draft minutes of each meeting will be provided to each Party by the chairperson, or his or her designee, after each meeting, and such minutes will be reviewed by the JDC members,
any needed changes discussed and final minutes agreed to and provided to each Party within [***] ([***]) days after each meeting unless otherwise agreed. A reasonable number of additional representatives of a Party may attend meetings of the JDC in
a non-voting capacity. Each Party is responsible for its personnel and travel costs and expenses associated with attending meetings. 
  

	 	(B)	 JDC functions and powers 

The responsibilities of the JDC will be as follows: 
  

	 	(1)	 encouraging and facilitating communication between the Parties with respect to the development of Licensed
Product(s)) and the Research and Technical Development Plan Activities; 

  

	 	(2)	 [***] the applicable Research and Technical Development Plan’s objectives, goals and schedules, and
reviewing and approving amendments to the applicable Research and Technical Development Plan, [***] 

  

	 	(3)	 [***], discussing and [***] the progress of the development of Licensed Product, each Party’s progress
with respect to the Research and Technical Development Plan Activities for which it is responsible and each Party’s diligence in carrying out its responsibilities under the applicable Research and Technical Development Plan; and

  

	 	(4)	 carrying out the other duties and responsibilities described for it in this Agreement. 

 

	(C)	 JDC decision making 

 

	 	(1)	 All decisions of the JDC will be made by unanimous vote, with each of Ascendis and Licensee having one vote and
the decisions will be recorded in the JDC minutes. If after reasonable discussion and consideration of each of the Parties’ views on a particular matter before the JDC, the JDC is unable to reach a decision by unanimous vote on that matter,
then [***] 

 The JDC shall not have any authority other than that expressly set forth above and, specifically, shall have
no authority: (x) to amend or interpret this Agreement; (y) to determine whether or not a Party has met its diligence or other obligations under the Agreement; or (z) to determine whether or not a breach of this Agreement has
occurred. 

  
 12 

	(D)	 Termination of JDC 

The JDC shall terminate in respect of a Research and Technical Development Plan upon completion by both Parties of their respective Research
and Technical Development Plan Activities, unless the Parties otherwise agree. 
  

	5.	 Manufacturing 

 

	5.1	 Concurrently with the execution of this Agreement, the Parties have entered into that certain clinical supply
agreement (the “Clinical Supply Agreement”) pursuant to which Ascendis will supply Licensed Product to Licensee for Licensee’s conduct of clinical trials for the Licensed Product in the Territory on the terms and conditions set
forth in the Clinical Supply Agreement. The Parties shall discuss and negotiate in good faith the terms and conditions for the supply by Ascendis of Licensed Product to the Licensee for commercial use upon the written request of Licensee, and in any
event starting no later than the date that is [***] ([***]) days after the initiation of the first pivotal clinical trial for the Licensed Product conducted by or behalf of Licensee in the Field and in the Territory. 

 

	5.2	 The Licensee shall, and it shall procure that its Affiliates and any
Sub-Licensees shall: 

  

	 	(A)	 [***] relating to the sale of Licensed Product comply with Applicable Laws and are marked, where required, with
all relevant patent numbers; and 

  

	 	(B)	 conduct all packaging and distribution in accordance with current Good Manufacturing Practice and Good
Distribution Practice. 

  

	6.	 Regulatory 

 

	6.1	 The Licensee shall have the sole responsibility for obtaining and maintaining, and shall own, all Regulatory
Approvals for Licensed Product developed under this Agreement from Regulatory Authorities in each of the jurisdictions in the Territory in the Field. 

  

	6.2	 Ascendis hereby grants to the Licensee, its Affiliates and
Sub-licensees the right to access, reference and utilize any data (including clinical trial data) or regulatory filings generated and/or filed by or on behalf of Ascendis or its Affiliates or other licensees
(in each case, to the extent Controlled by Ascendis or its Affiliates) with respect to Licensed Product(s)) in connection with the development, Manufacturing and commercialisation by the Licensee, its Affiliates and
Sub-licensees of Licensed Product(s) in the Territory, free of additional charge, as set forth herein. Upon written request from Licensee to be provided access to any such information, Ascendis shall provide
such access to Licensee within a reasonable time frame, taking into account the development and regulatory activities conducted by or on behalf of Ascendis for the Licensed Products outside of the Territory. Ascendis hereby represents and warrants
that, as of the Effective Date, it and/or its Affiliates Control all data and regulatory filings generated and/or filed by or on behalf of Ascendis or its Affiliates or other licensees with respect to the Licensed Product and Ascendis has the right
to grant the right to access, reference and utilization to Licensee, its Affiliates and Sub-licensees thereto. During the Term, Ascendis and/or its Affiliates shall maintain the right to all data and
regulatory filings generated and/or filed by or on behalf of Ascendis or its Affiliates or other licensees with respect to the Licensed Product (including by reserving the rights from any Third Party generating, filing and/or having rights to any
and all such data and/or regulatory filings) so that Ascendis and/or its Affiliates retains Control of such data and regulatory filings and can grant the right to access, reference and utilization to Licensee, its Affiliates and Sub-licensees under this Section 6.2. 

  
 13 

	6.3	 The Licensee hereby grants to Ascendis the right to access, reference and utilize any data (including clinical
trial data) or regulatory filings generated and/or filed by or on behalf of the Licensee or its Affiliates or sublicensees (in each case, to the extent Controlled by Licensee or its Affiliates) with respect to Licensed Product(s) in connection with
the development, Manufacturing and commercialisation by Ascendis, its Affiliates or other licensees of Licensed Product(s) outside the Territory, free of additional charge, as set forth herein. Upon written request from Ascendis to be provided
access to any such information, Licensee shall provide such access to Ascendis within a reasonable time frame, taking into account the development and regulatory activities conducted by or on behalf of Licensee for the Licensed Products in the Field
in the Territory. During the Term, Licensee and/or its Affiliates shall maintain the right to all data and regulatory filings generated and/or filed by or on behalf of Licensee or its Affiliates or
Sub-licensees with respect to the Licensed Product (including by reserving the rights from any Third Party generating, filing and/or having rights to any and all such data and/or regulatory filings) so that
Licensee and/or its Affiliates retains Control of such data and regulatory filings and can grant the right to access, reference and utilization to Ascendis, its Affiliates and other licensees under this Section 6.2. 

 

	6.4	 The Licensee undertakes to comply, and to procure that its
Sub-Licensees and contractors comply, with all requirements of Regulatory Authorities and/or Applicable Law and relevant guidance. 

 

	6.5	 Ascendis shall provide assistance and information as reasonably requested by the Licensee in support of such
regulatory activities[***]. 

  

	7.	 Payments 

 

	7.1	 Upfront 

  

	 	 As a one-time, non-refundable
consideration of the rights and licence granted by Ascendis to Licensee under this Agreement, Licensee shall issue and transfer to Ascendis [***] Series A-1 Preferred Shares in VISEN Pharmaceuticals,
corresponding to a total value of US[***] at the Effective Date. 

  

	7.2	 Research and development funding 

 

	 	 The Licensee shall pay or reimburse (as applicable) Ascendis for the Research and Technical Development Plan
Expenses in accordance with the schedule set forth in the Research and Technical Development Plans. 

  

	7.3	 Taxes 

  

	 	 In the event that the Licensee is required, under applicable laws, to withhold any deduction or tax from any
payment due to Ascendis under this Agreement, such amount shall be deducted from the payment to be made by the Licensee, paid to the proper taxing authority, provided that the Licensee shall take reasonable and lawful actions to avoid and minimise
such withholding and promptly notify Ascendis so that Ascendis may take lawful actions to avoid and minimise such withholding. Each Party agrees to cooperate with the other Party in claiming exemptions from such deductions or withholdings under any
agreement or treaty from time-to-time in effect. 

  
 14 

	 	 All sums payable by the Licensee under or pursuant to this Agreement [***] (if applicable). The taxable supply
of services made under or in connection with this Agreement by Ascendis to the Licensee are [***]. The Parties agree that they will undertake commercially reasonable efforts to minimize or eliminate any VAT liability, including but not
limited to [***]. 

  

	7.4	 Interest 

  

	 	 Where any fees, milestones or other sums payable by the Licensee to Ascendis hereunder remain unpaid after the
date on which they became due, the Licensee shall pay to Ascendis interest calculated from the date upon which the sums became due until payment thereof at the rate, to the extent permitted by applicable law, equal to the average one-month US Dollar London Interbank Offered Rate (LIBOR) as determined for each Quarterly Period on the last Business Day of such Quarterly Period (it being understood that if such rate is below zero percent
(0%) for any period it shall be deemed to be zero percent (0%) for such period for the purposes of this Clause 7.4) plus [***] percent ([***]%). 

  

	8.	 Records and Auditing 

 

	8.1	 Each Party will maintain complete and accurate books, records and accounts used for the determination of any
payment obligations under this Agreement, which books, records and accounts will be retained by such Party until [***] ([***]) years after the end of the period to which such books, records and accounts pertain. The Licensee shall make such books,
records and accounts available to Ascendis for an additional [***] ([***]) years if reasonably available and required by the applicable tax authority. 

  

	9.	 Pharmacovigilance 

 

	9.1	 After the execution of this Agreement, the Parties shall promptly, and in any event before the Licensee starts
any clinical development activities, agree on the terms of a safety data exchange agreement (the “SDEA”) for the collection, reporting and exchange of safety information. The scope of the SDEA shall also include the Licensee’s
Affiliates and Sub-Licensees, as applicable. 

  

	9.2	 Each Party shall notify the other Party of any “serious adverse experience” or “unexpected
adverse experience” (as defined below) and will manage the same, both in accordance with the terms of the SDEA. For the purpose of this Clause 9.2, “serious adverse experience” and “unexpected adverse experience” shall have
the meaning assigned by relevant regulations (to the extent applicable). To the extent relevant regulations require harmonisation or are not applicable, then each of the foregoing terms shall be as defined in the SDEA. 

 

	10.	 Confidentiality 

 

	10.1	 During the term of this Agreement, and for a period of [***] ([***]) years thereafter, the Licensee agrees to
keep secret Ascendis’ Confidential Information, to use the same exclusively as permitted under this Agreement, and to disclose the same only to those of its employees, contractors, consultants, Affiliates and
Sub-Licensees to whom and to the extent that such disclosure is reasonably necessary in order to exercise its rights and perform its obligations under this Agreement. 

 

	10.2	 During the term of this Agreement, and for a period of [***] ([***]) years thereafter, Ascendis agrees to keep
secret the Licensee’s Confidential Information, to use the same exclusively as permitted under this Agreement, and to disclose the same only to those of its employees, contractors, Affiliates,
Sub-Licensees and licensees to whom and to the extent that such disclosure is reasonably necessary in order to exercise its rights and perform its obligations under this Agreement. 

  
 15 

	10.3	 Each Party shall procure that all its employees, contractors, Affiliates and
Sub-Licensees who have access to any Confidential Information of the other to which the obligations of Clauses 10.1 or 10.2 as the case may be apply, shall be made aware of, subject to, and comply with those
obligations. Without limiting the foregoing, each Party shall take at least those measures it employs to protect its own confidential information of a similar nature to protect the other Party’s Confidential Information, but in any event no
less than reasonable care. 

  

	10.4	 The foregoing obligations of Clauses 10.1 and 10.2 shall not apply to any Confidential Information of the
disclosing Party which: 

  

	 	(A)	 prior to the recipient Party’s receipt thereof from the disclosing Party, was in the possession of the
recipient Party without any breach of confidentiality and at its free disposal; 

  

	 	(B)	 is subsequently lawfully disclosed to the recipient Party without any breach of confidentiality by an
independent Third Party, and at the recipient Party’s free disposal; 

  

	 	(C)	 is or becomes generally available to the public through no act or default of the recipient Party or its agents,
contractors or employees; or 

  

	 	(D)	 is independently developed by the receiving Party without the benefit of any Confidential Information disclosed
hereunder, as demonstrated by documented evidence prepared contemporaneously with such independent development. 

  

	10.5	 Notwithstanding the foregoing, a Party and its Affiliates and
Sub-Licensees may use and disclose the Confidential Information of the other Party: 

  

	 	(A)	 if it is required to be disclosed by law, regulation or action of any governmental agency or authority,
including as may be required in connection with any filings made with, or by the disclosure policies of a major stock exchange; provided that the Party seeking to disclose the Confidential Information of the other Party: (i) promptly informs
the other Party (prior to making any such disclosures, if practicable) and cooperates with the other Party in seeking a protective order or other appropriate remedy (including redaction); and (ii) whenever it is possible to obtain confidential
treatment, request confidential treatment of such information; 

  

	 	(B)	 as reasonably necessary to obtain or maintain any Regulatory Approval, including to conduct preclinical studies
and clinical trials and for pricing approvals, for any Licensed Product, provided that, the disclosing Party shall use commercially reasonable efforts to limit disclosure of the Confidential Information outside such regulatory agency and to
otherwise maintain the confidentiality of the Confidential Information; or 

  

	 	(C)	 as reasonably necessary to exercise its rights or fulfil its obligations under this Agreement.

  

	10.6	 The Licensee and its Affiliates and Sub-Licensees may disclose the
Confidential Information of Ascendis to contractors, consultants and other service providers in connection with the development or Manufacture of Licensed Product(s) under conditions of confidentiality at least as restrictive as those contained in
this Clause 10 and/or as is standard for similar deals in the biotechnology industry. 

  
 16 

	10.7	 If a Party concludes that a copy of this Agreement must be filed with the United States Securities Exchange
Commission or other regulatory agency (“SEC”) (or equivalent foreign agency or a securities exchange), such Party will use all reasonable efforts to provide the other Party with a copy of this Agreement showing any provisions hereof as to
which the Party proposes to request confidential treatment, and to provide the other Party with an opportunity to comment on any such proposed redactions and to suggest additional redactions. The filing Party will take such other Party’s
reasonable comments into consideration before filing the Agreement. 

  

	10.8	 Each Party (“Publishing Party”) shall submit to the other Party manuscripts, including
abstracts, and texts of poster presentations and other external presentations containing the other Party’s Confidential Information at least [***] ([***]) days prior to presentation or submission for publication for purposes of allowing the
other Party to comment on the manuscript or text; provided that the other Party may require the Publishing Party, by giving notice in writing to the Publishing Party within [***] ([***]) days of the receipt of such manuscript, abstract, text or
other external presentations from the Publishing Party to redact certain information or delay submission for publication or presentation of such manuscript, abstract, text or other external presentation if, in the reasonable opinion of the other
Party such delay is necessary in order to permit the filing of any patent application or to protect the other Party’s Confidential Information contained in such manuscript, abstract, text or other external presentation. 

 

	10.9	 The Licensee, in accordance with its internal policies and procedures, shall have the right to publish all
studies, clinical trials and results thereof on the clinical trial registries that are maintained by or on behalf of the Licensee. Ascendis shall not publish any studies, clinical trials or results thereof on its clinical trial registry, provided
however, that Ascendis may include on Ascendis’ clinical trial registry a link to the Licensee’s clinical trial registry. 

  

	10.10	 Notwithstanding the foregoing, each Party shall have the right to disclose the terms and conditions of this
Agreement: (i) in confidence (i.e., pursuant to a written confidentiality agreement containing terms at least as stringent as those contained in this Agreement) to any bona fide potential or actual investor, investment banker, auditor, counsel,
acquirer or merger target; and (ii) subject to the prior written consent of the other Party, such consent not to be unreasonably withheld, for the purpose of a public offering or private placement of shares and/or securities.

  

	11.	 Intellectual Property  

 

	11.1	 All Patents and Technical Information and other Intellectual Property owned or Controlled by a Party prior to
the Effective Date shall remain owned or Controlled by the respective Party. 

  

	11.2	 Ascendis and the Licensee acknowledge and agree that as between them: 

 

	 	(A)	 Ascendis (or its Affiliates) shall own all right, title and interest in and to any and all Ascendis Patents
(except for Ascendis Patents within the Joint Program IP), Ascendis Technical Information (except for Ascendis Technical Information within the Joint Program IP) and Ascendis Program IP; 

 

	 	(B)	 the Licensee shall own all right, title and interest in and to any and all Licensee Program IP; and

  
 17 

	 	(C)	 the Licensee and Ascendis (or its Affiliates) shall each own an undivided fifty percent (50%) right, title and
interest in and to any and all Joint Program IP. For the avoidance of doubt, subject to the licences granted under this Agreement, each Party shall be free to exploit, transfer or encumber its own interest in the Joint Program IP without the consent
of, and without accounting to, the other Party. For those jurisdictions where a specific license is required for a joint owner of Joint Program IP to practice such Joint Program IP in such jurisdictions: (i) Ascendis hereby grants to Licensee a
perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up, transferable and sublicensable license under Ascendis’s right, title and interest in and to all Joint Program IP to use such
Joint Program IP in accordance with the terms of this Agreement; and (ii) Licensee hereby grants to Ascendis a perpetual, irrevocable, non-exclusive, worldwide, royalty-free, fully paid-up, transferable and sublicensable license under Licensee’s right, title and interest in and to all Joint Program IP to use such Joint Program IP in accordance with the terms of this Agreement. Each Party
shall promptly notify the other Party after it first learns of the conception of a Joint Program IP by such Party, its employees, officers, or independent contractors, and provide the other Party with a detailed report of the underlying data,
results, experimental procedures related to, and inventors of, such Joint Program IP. 

  

	11.3	 Notwithstanding the foregoing, [***]. 

 

	12.	 Prosecution, Maintenance and Defence 

 

	12.1	 Subject to Clause 12.4, Ascendis shall, at its own expense and in its sole discretion, have the right to file,
prosecute, maintain and defend the Ascendis Patents that are not Joint Program IP Patents (as defined in Clause 12.3(A) (including without limitation Licensed Product Patents as well as any Ascendis Patent claiming Ascendis Platform Technology that
are not Joint Program IP Patents). Solely with respect to the Licensed Product Patents in the Territory that are not within the Joint Program IP, Ascendis will promptly provide the Licensee with drafts of all proposed filings and correspondence
(including without limitation the initial application as well as any material correspondence with any Intellectual Property Office in the Territory related to any filings) in a manner that allows the Licensee a reasonable opportunity for
review and comment (and in any event no less than [***] ([***]) days, if and when possible) before such filings are due. Ascendis will consider all of the Licensee’s reasonable suggestions, recommendations and instructions concerning the
preparation, filing, prosecution, defence and maintenance of any such Patents (including without limitation any suggestion or recommendation [***]), provided that such reasonable suggestions, recommendations and instructions are provided to Ascendis
within [***] ([***]) days of the Licensee receiving any such proposed filings and correspondence. If Ascendis does not wish to file, prosecute or maintain any such Licensed Product Patent which is not within the Joint Program IP, or if Ascendis
wishes to allow any such Patent to lapse, in each case, solely within the Territory, then [***], Ascendis shall notify Licensee in writing of such decision at least [***] ([***]) days prior to any action relating to such Patent is required, and
Licensee shall then have the option, at its sole discretion, to file, prosecute, and/or maintain such Patent, at its sole cost and expense. 

  

	12.2	 Subject to Section 12.4, the Licensee shall, at its own expense and in its sole discretion, have the right
to file, prosecute, maintain and defend any Patent within the Licensee Program IP. If Licensee does not wish to file, prosecute or maintain any such Patent within the Licensee Program IP, or if Licensee wishes to allow any such Patent to lapse, in
each case, solely outside of the Territory, then [***], Licensee shall notify Ascendis in writing of such decision at least [***] ([***]) days prior to any action relating to such Patent is required, and Ascendis shall then have the option, at its
sole discretion, to file, prosecute, and/or maintain such Patent, at its sole cost and expense. 

  
 18 

	12.3	 Joint Program IP 

 

	 	(A)	 Subject to Clause 12.4, the Prosecuting Party (as defined below) shall select outside patent counsel
(“Outside Patent Counsel”) at its sole discretion to file, prosecute and maintain any Patent within the Joint Program IP in the joint names of the Parties (“Joint Program IP Patent”). [***] shall have the first
right, at its sole expense and in its sole discretion, to engage Outside Patent Counsel to file, prosecute and maintain all Joint Program IP Patents, and [***] shall have the backup right to file, prosecute, and maintain such Joint Program IP
Patents in the Territory in accordance with Clause 12.3(C). The Party that exercises its right to file, prosecute and maintain a particular Joint Program IP Patent in accordance with this Clause 12.3 shall be referred to as the “Prosecuting
Party”. 

  

	 	(B)	 With respect to Joint Program IP Patents, the Prosecuting Party will (or will cause Outside Patent Counsel to)
promptly provide the other Party with drafts of all proposed filings and correspondence (including without limitation the initial application as well as any material correspondence with any Intellectual Property Office related to any filings)
in a manner that allows the other Party a reasonable opportunity for review and comment (and in any event no less than [***] ([***]) days, if and when possible, before such filings are due). The Prosecuting Party will (or will cause Outside Patent
Counsel to) consider all of the other Party’s reasonable suggestions, recommendations and instructions concerning the preparation, filing, prosecution, defence and maintenance of any such Joint Program IP Patents (including without limitation
any suggestion or recommendation [***]), provided that such reasonable suggestions, recommendations and instructions are provided to the Prosecuting Party (or Outside Patent Counsel) within [***] ([***]) days of the other Party receiving any such
proposed filings and correspondence. 

  

	 	(C)	 If [***] as the Prosecuting Party elects: (1) not to file, prosecute or maintain a Joint Program IP Patent
(whether in one or more jurisdictions); or (2) to allow any such Patent to lapse or become abandoned or unenforceable, in each case, in accordance with Clause 12.3(A), then [***] shall notify [***] in writing at least [***] ([***]) days prior
to the lapse or abandonment of any such Patent. Thereafter, [***] may, but is not required to, undertake, at its sole expense and in its sole discretion, and using Outside Patent Counsel, the prosecution and maintenance of such Joint Program IP
Patent, but solely within the Territory, and in such case, [***] shall become the Prosecuting Party with respect to such Patent in the Territory. 

  

	12.4	 Notwithstanding any other provision of this Clause 12, [***] 

 

	12.5	 The Parties agree to cooperate reasonably in the filing, prosecution and maintenance of all Patents as set
forth under this Clause 12 including providing relevant Technical Information to the prosecuting Party (as determined in accordance with this Clause 12), obtaining and executing necessary powers of attorney and assignments by the named inventors,
obtaining execution of such other documents which may be needed in the filing, prosecution and maintenance of each such Patent, and, as requested, updating each other regarding the status of each such Patent, and shall cooperate with the other Party
so far as reasonably necessary with respect to furnishing all information and data in its possession and Control that is reasonably necessary to prosecute and maintain such Patents. 

  
 19 

	13.	 Enforcement of Patent Rights and Defence of Third Party Claims 

 

	13.1	 Infringement by a Third Party 

 

	 	(A)	 In the event of Ascendis or the Licensee becoming aware of any suspected infringement or any unauthorised use
by a Third Party of any of the Ascendis Patents, Ascendis Technical Information, Ascendis Program IP, Licensee Program IP, and/or the Joint Program IP in the Field in the Territory, the Party becoming aware of the same shall promptly notify the
other Party. 

  

	 	(B)	 Where such suspected infringement or unauthorised use is of the Ascendis Patents or Ascendis Technical
Information (including those within the Joint Program IP and/or Ascendis Program IP), in each case (i) outside the Territory, or (ii) inside the Territory but outside the Field, Ascendis shall, at its own expense, have the exclusive
right, but not the obligation, to take or threaten any legal action that it deems appropriate to halt such suspected infringement and to retain any amounts recovered in respect of such suspected infringement or unauthorised use. Termination and/or
settlement of the litigation are at the sole discretion of Ascendis (i.e., without the prior consent of the Licensee), provided such termination or settlement does not impose a liability (monetary or otherwise) on Licensee or limit the rights of
Licensee under this Agreement, or otherwise materially impair Licensee’s rights in the relevant Ascendis Patent in each case without Licensee’s prior written consent. 

 

	 	(C)	 Where such suspected infringement or unauthorised use is of the Ascendis Patents Ascendis Technical Information
(including those within the Joint Program IP and/or any Ascendis Program IP), in each case in the Field in the Territory, the Licensee shall, at its own expense, have the first right, but not the obligation to take or threaten any legal action that
it deems appropriate to halt such suspected infringement (provided that [***]). Each Party shall retain the following percent of any remaining amounts recovered in respect of such suspected infringement or unauthorised use after the Licensee has
recouped its expenses: the Licensee shall retain [***] percent ([***]%) and Ascendis shall retain [***] percent ([***]%). Termination and/or settlement of the litigation are at the sole discretion of the Licensee (i.e., without the prior consent of
Ascendis), provided such termination or settlement does not impose a liability (monetary or otherwise) on Ascendis or limit the rights of Ascendis under this Agreement, or otherwise materially impair Ascendis’s rights in the relevant Ascendis
Patent in each case without Ascendis’s prior written consent. 

  

	 	(D)	 If Ascendis wishes to take or threaten legal action and the Licensee has the first right to do so under Clause
13.1(C), but does not do so within [***] ([***]) days of becoming aware of potential infringement, then Ascendis may take or threaten such legal action and the Licensee shall, at Ascendis’ request, lend its name where necessary or desirable to
proceedings relating to such action and provide reasonable assistance in such proceedings. In such circumstances, Ascendis shall control the conduct of the action but shall consult the Licensee in good faith with regard to significant decisions.
Each Party shall retain the following percent of any remaining amounts recovered in respect of such suspected infringement or unauthorised use after Ascendis has recouped its expenses: Ascendis shall retain an amount equal to [***] percent ([***]%)
and the Licensee shall retain the remaining [***] percent ([***]%). Termination and/or settlement of the litigation are at the sole discretion of Ascendis (i.e., without the prior consent of the Licensee). 

  
 20 

	 	(E)	 Each Party shall provide to the Party enforcing any such rights under this Clause 13.1 reasonable assistance in
such enforcement, at such enforcing Party’s request and expense, including joining such action as a party plaintiff if required by Applicable Laws to pursue such action. The enforcing Party shall keep the other Party regularly informed of the
status and progress of such enforcement efforts and shall reasonably consider the other Party’s comments on any important aspects of such enforcement, including determination of litigation strategy and filing of important papers to the
competent court. 

  

	13.2	 Defence of Third Party Claims 

 

	 	(A)	 In the event that the development or commercialisation of a Licensed Product results in action by a Third Party
against a Party (or its Affiliates or Sub-Licensees) for infringement or unauthorised use of Intellectual Property or confidential information anywhere in the Territory, such Party shall promptly notify the
other Party in writing. 

  

	 	(B)	 Each Party (or its Affiliates or Sub-Licensees) against whom such
action is brought shall: (i) have the right but not the obligation to defend such action; (ii) have the right to be represented by separate legal advisors; (iii) keep the other Party informed of, and assist and co-operate with the other Party in, any such action; and (iv) bear its own costs. 

  

	14.	 Warranties 

 

	14.1	 Each Party warrants to the other Party that it: 

 

	 	(A)	 is free to enter into this Agreement and to carry out its obligations hereunder without violating any
obligation owed by it or any of its Affiliates to any Third Party; 

  

	 	(B)	 shall not, during the existence of this Agreement, enter into any assignments, licences, obligations, charges
or assignments, either written, oral or implied, which are or shall be inconsistent with this Agreement; 

  

	 	(C)	 has obtained all necessary corporate approvals to enter into and execute this Agreement; 

 

	 	(D)	 has never been debarred, disqualified or banned from practising medicine and that it is not under investigation
by any Regulatory Authority for debarment, disqualification or any similar regulatory action in any country. 

  

	14.2	 Ascendis represents and warrants to the Licensee that, as of the Effective Date, Ascendis:

  

	 	(A)	 Controls the Ascendis Patents and Ascendis Technical Information in the Field in the Territory;

  

	 	(B)	 has the right to grant to the Licensee the rights and licences granted to the Licensee under the terms and
conditions of this Agreement, 

  

	 	(C)	 has the right to provide and disclose to the Licensee the Ascendis Technical Information that it provides or
discloses to the Licensee under the terms and conditions of this Agreement; 

  

	 	(D)	 itself and its employees have not received notice of any actions, lawsuits, claims or arbitration or material
adverse proceedings (other than on-going routine patent prosecution matters) in any way relating to the Ascendis Patents, Ascendis Technical Information or Ascendis Platform Technology; and

  
 21 

	 	(E)	 is not, to [***] its knowledge, aware that the use of Licensed Product Patents in Schedule 1, the Ascendis
Patents existing as of the Effective Date, and/or Ascendis Technical Information listed in Schedule 2, for development or commercialisation of a Licensed Product infringes any Third Party’s Patent. 

 

	 	(F)	 there are no patents, patent applications or Technical Information that are owned or in-licensed by Ascendis and/or its Affiliates that Ascendis and/or its Affiliates do not Control and are not included in the license granted to Licensee under this Agreement, which would be infringed by or would
otherwise cover the development, manufacture and/or commercialization of the Licensed Product in the Field in the Territory. During the Term, Ascendis and/or its Affiliates shall maintain the Control of patents, patent applications and/or Technical
Information that are then-owned or then-in-licensed by Ascendis and/or its Affiliates that would be infringed by or would otherwise cover the development, manufacture
and/or commercialization of the Licensed Product in the Field in the Territory (including by reserving such rights from any Third Party carrying out the development, manufacture and/or commercialization of the Licensed Product on behalf of or under
a license from Ascendis or its Affiliates) so that such patents, patent applications and/or Technical Information are included in the license granted to Licensee hereunder; provided, that for clarity this provision shall not be deemed to impose any
obligation on Ascendis to obtain ownership or license rights to any patents, patent applications, Technical Information, or intellectual property rights of any Third Party. 

 

	14.3	 EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF
ANY KIND WITH RESPECT TO INTELLECTUAL PROPERTY RIGHTS OR CONFIDENTIAL INFORMATION SUPPLIED BY IT TO THE OTHER PARTY HEREUNDER, AND EXPRESSLY DISCLAIMS ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING BUT NOT LIMITED TO WARRANTIES OF MERCHANTABILITY,
FITNESS FOR A PARTICULAR PURPOSE AND NON-INFRINGEMENT. 

  

	15.	 Indemnification 

 

	15.1	 Except as provided in Clause 15.2 below, the Licensee shall indemnify, defend and hold harmless Ascendis and
its Affiliates, and their respective directors, officers, employees and agents (each an “Ascendis Indemnitee”) from and against all Losses arising out of or resulting from any Third Party Claims to the extent such Losses result from
or arise out of: (a) the activities performed by the Licensee in connection with the exercise of its rights or obligations under this Agreement (including the exploitation of the Licensed Product(s) in the Territory); (b) breach by the Licensee
of the representations and warranties provided in Clause 14; (c) gross negligence, recklessness or wilful misconduct by the Licensee; or (d) violation of Applicable Law by the Licensee. The indemnification obligations set forth in this Clause
15.1 shall not apply to the extent that any such Losses arising from such Third Party Claim arose or resulted from the events specified in Clause 15.2(a)-(d). 

 

	15.2	 Except as provided in Clause 15.1 above, Ascendis shall indemnify, defend and hold harmless the Licensee, its
Affiliates, and their respective directors, officers, employees and agents (each a “Licensee Indemnitee”) from and against all Losses arising out of or resulting from any Third Party Claims to the extent such Losses result from or
arise out of: (a) the activities performed by Ascendis, its Affiliates, and Sublicensees in connection with the exercise of its rights or obligations under this Agreement, including the exploitation of the Licensed Product(s) outside of the
Territory; (b) breach by Ascendis of the representations and warranties provided in Clause 14; (c) gross negligence, recklessness or wilful misconduct by Ascendis, its Affiliates, and Sublicensees; or (d) violation of Applicable Law by
Ascendis, its Affiliates, and Sublicensees. The indemnification obligations set forth in this Clause 15.2 shall not apply to the extent that any such Third Party Claim arose or resulted from the events specified in Clause 15.1(a)-(d).

  

  
 22 

	15.3	 In the event that an Ascendis Indemnitee or a Licensee Indemnitee, as applicable (hereinafter an
“Indemnified Party”) seeks indemnification under this Clause 15, such Indemnified Party shall: (i) give prompt notice to the indemnifying Party of any such Third Party Claim; (ii) permit the indemnifying Party to assume
direction and control of the defence of such Third Party Claim (including decisions regarding its settlement or other disposition, which may be made in the indemnifying Party’s sole discretion except as otherwise provided herein); (iii) assist
the indemnifying Party at the indemnifying Party’s expense in defending such Third Party Claim; and (iv) not compromise or settle such Third Party Claim without the indemnifying Party’s prior written consent, which shall not be
unreasonably withheld or delayed. The failure to deliver written notice to the indemnifying Party within a reasonable time after the commencement of any such Third Party Claim, to the extent prejudicial to its ability to defend such Third Party
Claim, shall relieve the indemnifying Party of any obligation to the Indemnified Party under this Clause 15. The Indemnified Party may participate in the defence of such Third Party Claim through counsel of its choice, but the reasonable cost of
such counsel shall be borne solely by the Indemnified Party. It is understood that only Ascendis or the Licensee may claim indemnity under this Clause 15 (on its own behalf or on behalf of its Indemnified Parties), and other Indemnified Parties may
not directly claim indemnity hereunder. No compromise or settlement of any Third Party Claim may be effected by the indemnifying Party without the Indemnified Party’s prior written consent (which consent shall not be unreasonably withheld or
delayed), unless: (a) there is no finding or admission of any violation of law or any violation of the rights of any person and no effect on any other claims that may be made against the Indemnified Party; (b) the sole relief provided is
monetary damages that are paid in full by the indemnifying Party; and (c) the Indemnified Party’s rights under this Agreement are not adversely affected. The Indemnified Party shall have no right to settle any such Third Party Claim
without the prior written consent of the indemnifying Party (and any such settlement without the prior written consent of the indemnifying Party shall relieve the indemnifying Party of its obligations under this Clause 15), unless: (x) there is
no finding or admission of any violation of law or any violation of the rights of any person and no effect on any other claims that may be made against the Indemnifying Party; (y) the sole relief provided is monetary damages that are paid in
full by the Indemnified Party; and (z) the indemnifying Party’s rights under this Agreement are not adversely affected. 

  

	16.	 Limitation of Liability 

 

	16.1	 Subject to Clause 16.2, neither of the Parties nor any of their Affiliates shall be liable to each other under
any contract, negligence, strict liability or other legal or equitable theory for indirect, incidental, special, punitive, exemplary or consequential damages arising out of or resulting from this Agreement. The foregoing shall not limit:

  

	 	(A)	 the obligations of either Party from and against Third Party claims under Clauses 15.1 or 15.2 to the extent
that such Third Party has been awarded such damages; 

  

	 	(B)	 the liability of a Party as a result of its breach of Clause 10; or 

 

	 	(C)	 the liability of either Party under Clause 2.3.  

  
 23 

	16.2	 Neither Party limits or excludes its liability for fraud, fraudulent concealment or fraudulent
misrepresentation, nor for death or personal injury arising from its negligence. 

  

	16.3	 Ascendis and Ascendis Pharma A/S shall be jointly and severally liable for any liabilities incurred by or on
behalf of Ascendis under this Agreement. 

  

	17.	 Term and Survival 

 

	17.1	 This Agreement shall commence with effect from the Effective Date and shall continue for so long as a Valid
Claim of an Ascendis Patent exists in the Territory, unless terminated earlier pursuant to Clause 18. 

  

	17.2	 On the expiration or other termination of this Agreement each Party shall continue to be bound by Clauses 2.2
(solely in the event of expiration, or as it may be modified by Clause 19.3 in specified events of termination), 8 (Records and Auditing), 9.2 (Pharmacovigilance), 10 (Confidentiality), 11.1 and 11.2 (Intellectual Property), 15 (Indemnification), 16
(Limitation of Liability), 17 (Term and Survival), 19 (Effect of Termination), 20 (Dispute Resolution) and 21 (Miscellaneous). 

  

	18.	 Termination 

 

	18.1	 Licensee termination for convenience 

 

	 	 The Licensee may terminate this Agreement at any time for any reason by giving ninety (90) days’
prior written notice to Ascendis. 

  

	18.2	 Right to Terminate for Material Breach  

 

	(a)	 In the event that Ascendis commits a material breach of any of the terms of this Agreement on its part to be
performed or observed, Licensee shall have the right to terminate this Agreement, in whole or in part, by giving sixty (60) days’ written notice to Ascendis; provided, however, that in the case of a material breach capable of being
remedied, if Ascendis shall remedy such material breach within sixty (60) days after the notice has been given, then the notice shall not be effective and the Agreement shall not terminate. 

 

	(b)	 In the event that Licensee commits a material breach of any of the material obligations under Section 2.3,
7.1, 7.2 or 10 and such material breach causes material loss by Ascendis that exceeds [***] dollars ($[***]), Ascendis shall have the right to terminate this Agreement, in whole or in part, by giving ninety (90) days’ written notice to
Licensee; provided, however, that if Licensee shall remedy such material breach or reduce such loss below [***] dollars ($[***]) within ninety (90) days after the notice has been given, then the notice shall not be effective and the Agreement
shall not terminate. 

  

	18.3	 Right to Terminate for Bankruptcy  

 

	 	(A)	 Right to terminate 

A Party (the “Non-Bankrupt Party”) may, to the extent legally permissible and in
addition to any other remedies available to it by law or in equity, terminate this Agreement, as a whole by notice to the other Party (the “Bankrupt Party”), in the event the Bankrupt Party has become bankrupt, has made an
assignment for the benefit of its creditors or there has been appointed a trustee or receiver of the Bankrupt Party for all or a substantial part of its property or any case or proceeding shall have been commenced or other action taken by or against
the Bankrupt Party in bankruptcy or seeking reorganisation, liquidation, dissolution, winding-up, arrangement, composition or readjustment of its debts or any other relief under any bankruptcy, insolvency,
reorganisation or other similar act or law of any jurisdiction now or hereafter in effect and any such event shall have continued for sixty (60) days undismissed, unbonded and undischarged. 

  
 24 

	 	(B)	 Retention of rights upon Bankruptcy 

In the event of a bankruptcy of the Bankrupt Party, the rights and licences granted under or pursuant to this Agreement by the Bankrupt Party
to the Non-Bankrupt Party are, and shall otherwise be deemed to be, for purposes of paragraph 365(n) of the United States Bankruptcy Code, licences of rights to “intellectual property” as defined
under paragraph 101(35A) of the United States Bankruptcy Code. The Parties agree that the Non-Bankrupt Party, as a licensee of such rights under this Agreement, shall retain and may fully exercise all of its
rights and elections under the United States Bankruptcy Code. The Parties further agree that in the event of the commencement of a bankruptcy proceeding by or against the Bankrupt Party, including under the United States Bankruptcy Code, the Non-Bankrupt Party shall, to the extent legally permissible, be entitled to complete access to any such intellectual property of the Bankrupt Party that pertains to the rights granted in the licenses under this
Agreement and embodiments of such intellectual property. 
  

	18.4	 Ascendis termination for Change of Control. Ascendis may terminate this Agreement as a whole,
effective immediately upon written notice to Licensee, in the event of a Change of Control in favour of a Competitor. 

  

	18.5	 Ascendis termination for Patent challenge.  

 

	 	(A)	 Without limiting Clause 18.5(B), [***], Ascendis may terminate this Agreement as a whole effective upon thirty (30)-day written notice to the Licensee, if the Licensee or its Affiliates challenges [***] in a court the validity, [***] of any Ascendis Patent and such challenge is not withdrawn within such thirty (30)-day period, unless Ascendis or its Affiliates or any of its licensees has [***]. 

  

	 	(B)	 At any time during the Term, Ascendis may terminate this Agreement as a whole effective upon thirty (30)-day written notice to the Licensee, if the Licensee or its Affiliates challenges [***] in a court the validity, [***] of any (i) Ascendis Patent [***] or (ii) any Ascendis Patent [***], and in either
case of (i) or (ii), such challenge is not withdrawn within such thirty (30)-day period, unless Ascendis or its Affiliates or any of its licensees has [***]. 

 

	19.	 Effect of Termination 

 

	19.1	 The termination of this Agreement shall be without prejudice to: 

 

	 	(A)	 the obligation of the Licensee to pay to Ascendis all sums accrued, due and payable under Clause 7 as of the
effective date of termination; and 

  

	 	(B)	 any right of, or remedy available to, either Party against the other in respect of any action or omission
hereunder prior to such termination. 

  
 25 

	19.2	 Termination by the Licensee 

 

	 	(A)	 For Convenience 

In the event of termination of this Agreement in whole or in part by the Licensee pursuant to Clause 18.1: 

 

	 	(1)	 the licences granted to Ascendis and its Affiliates under Clause 2.2 shall [***], except that [***], and [***];

  

	 	(2)	 Licensee shall transfer, or cause to be transferred, all [***] existing as of the effective date of such
termination to Ascendis or its designee, [***], and [***]; 

  

	 	(3)	 the licences granted to the Licensee under Clause 2.1 shall terminate as of the effective date of such
termination; 

  

	 	(4)	 [***]; and 

  

	 	(5)	 obligations under Clause 2.3 shall cease for both Parties and their Affiliates. 

 

	 	(B)	 For Ascendis’ breach or bankruptcy 

In the event of termination of this Agreement in whole by the Licensee pursuant to Clauses 0 or 18.3(A), subject to Clause 19.5: 

 

	 	(1)	 the licence granted to the Licensee under Clause 2.1 (and all sublicenses granted thereunder) shall survive
(along with all obligations associated therewith) in respect of any Ascendis Patents, Ascendis Technical Information, Ascendis Program IP and Ascendis’ and its Affiliates’ interest in Joint Program IP that exist as of the effective date of
such termination; 

  

	 	(2)	 the licence granted to Ascendis and its Affiliates under Clause 2.2 shall survive (along with all obligations
associated therewith), in respect of the Licensee’s and its Affiliates’ interest in any Joint Program IP and Licensee Program IP that exist as of the effective date of such termination; 

 

	 	(3)	 [***]; 

  

	 	(4)	 if the effective date of such termination is prior to the [***] anniversary of the Effective Date, unless
otherwise agreed to by the Licensee, Ascendis’ obligations under Clause 5.1 shall survive until the [***] anniversary of the Effective Date; and 

  

	 	(5)	 Ascendis’ and its Affiliates’ obligations under Clause 2.3(A) shall survive until the [***]
anniversary of the effective date of such termination.  

  

	19.3	 Termination by Ascendis 

In the event of termination of this Agreement in whole or in part by Ascendis pursuant to Clauses 18.2, 18.3, 18.4 or 18.5, subject to Clause
19.4: 
  

	 	(A)	 the licence granted to Ascendis and its Affiliates under Clause 2.2 shall [***], except that [***], and
Ascendis [***]; 

  
 26 

	 	(B)	 Licensee shall transfer, or cause to be transferred, [***] existing as of the effective date of such
termination to Ascendis or its designee, [***], and Ascendis shall [***]; 

  

	 	(C)	 [***]; 

  

	 	(D)	 obligations under Clause 2.3 shall cease for both Parties and their Affiliates; and 

 

	 	(E)	 the licence granted to the Licensee under Clause 2.1 shall terminate as of the effective date of the
termination. 

  

	19.4	 Inventory at termination 

 

	 	 In the event this Agreement is terminated for any reason, the Licensee shall have the right to sell or
otherwise dispose of Licensed Product then in its stock for up to [***] ([***]) months following the termination of this Agreement. 

  

	19.5	 Continuation of sub-licences 

 

	 	 Upon termination of this Agreement, any existing, permitted sub-licence
granted by a Party under this Agreement shall continue in full force and effect, provided that the permitted Sub-Licensee did not cause the breach that gave rise to a termination under Clause 18.2 and agrees
to be bound by all the terms and conditions of this Agreement that are applicable to such permitted Sub-Licensee, including, without limitation, rendering directly to the licensing Party all payments and other
obligations due to the licensing Party related to such sub-licence. 

  

	19.6	 Return of Confidential Information 

 

	 	 Following any expiration or termination of this Agreement, the Party that has Confidential Information of the
other Party shall return to the other Party (or destroy at such Party’s written request) all such Confidential Information in its possession as of the effective date of expiration or termination (with the exception of one copy of such
Confidential Information, which may be retained by the legal department of the Party that received such Confidential Information to confirm compliance with the non-use and
non-disclosure provisions of this Agreement, and any Confidential Information of the other Party contained in its laboratory notebooks or databases. 

 

	20.	 Dispute Resolution 

 

	20.1	 Internal resolution 

 

	 	(A)	 Any dispute, controversy or claim related to matters within the powers and authority of the JDC shall be
resolved by the Parties in accordance with procedures set forth in Clause 4.6. 

  

	 	(B)	 Except as otherwise expressly provided herein, including in Clause 20.1(A) above, in the event of any
controversy, claim or other dispute arising out of or relating to compliance with this Agreement, or the validity, breach, termination or interpretation of this Agreement, such dispute shall be first referred to the Executives for resolution, prior
to proceeding under the following provisions of Clause 20.2. A dispute shall be referred to the Executives upon one Party providing the other Party with written notice that such dispute exists, and the Executives shall attempt to resolve such
dispute through good faith discussions. In the event that the Executives cannot resolve such dispute within [***] ([***]) days of such other Party’s receipt of such written notice, either Party may initiate the dispute resolution procedures set
forth in Clause 20.2. The Parties agree that any discussions between such Executives, or their designees, regarding such dispute shall be the Confidential Information of both Parties and do not constitute settlement discussions, unless the Parties
agree otherwise in writing. 

  
 27 

	20.2	 Arbitration 

Except as otherwise expressly provided in this Agreement, including but not limited to Clause 20.3, the Parties agree that any dispute not
resolved internally by the Parties pursuant to Clause 20.1(B), shall be resolved through binding arbitration conducted under the auspices of the [***] (for purposes of this Clause 20.2, the “Rules”), except as modified in this
Agreement, applying the substantive law specified in Clause 21.12 (Governing law). A Party may initiate arbitration by written notice to the other Party of its intention to arbitrate, and such demand notice shall specify in reasonable detail the
nature of the dispute. Each Party shall select one (1) arbitrator, and the two (2) arbitrators so selected shall choose a third arbitrator. All three (3) arbitrators shall serve as neutrals and have at least [***] ([***]) years of:
(a) dispute resolution experience (including judicial experience); and/or (b) legal or business experience in the biotech or pharmaceutical industry. In any event, at least one (1) arbitrator shall satisfy the foregoing experience
requirement under Clause 20.2(b). Notwithstanding anything to the contrary in this Clause 20.2, in the event of a dispute regarding the Prosecution and Maintenance activities described in Clause 12 at least one (1) arbitrator shall have
expertise in patent law. If a Party fails to nominate its arbitrator, or if the Parties’ arbitrators cannot agree on the third arbitrator, the necessary appointments shall be made in accordance with the Rules. Once appointed by a Party, such
Party shall have no ex parte communication with its appointed arbitrator. The arbitration proceedings shall be conducted in [***]. The arbitration proceedings and all pleadings and written evidence shall be in the English language. Any
written evidence originally in another language shall be submitted in English translation accompanied by the original or a true copy thereof. Each Party agrees to use commercially reasonable efforts to make all of its current employees available, if
reasonably needed, and agrees that the arbitrators may deem any party as “necessary.” The arbitrators shall be instructed and required to render a written, binding, non-appealable resolution and
award on each issue that clearly states the basis upon which such resolution and award is made. The written resolution and award shall be delivered to the Parties as expeditiously as possible, but in no event more than [***] ([***]) days after
conclusion of the hearing, unless otherwise agreed by the Parties. Judgment upon such award may be entered in any competent court or application may be made to any competent court for judicial acceptance of such an award and order for enforcement.
[***] The Parties may apply to any court of competent jurisdiction for a temporary restraining order, preliminary injunction or other interim or conservatory relief, as necessary, without breaching these arbitration provisions and without abridging
the powers of the arbitrators. At the request of either Party, the arbitrators shall enter an appropriate protective order to maintain the confidentiality of information produced or exchanged in the course of the arbitration proceedings. The
arbitrators shall have the power to decide all questions of arbitrability. The Parties agree that: (i) they shall share equally the fees and expenses of the arbitrators; and (ii) each Party shall bear its own attorneys’ fees and
associated costs and expenses. 
  

	20.3	 Patent validity 

Notwithstanding the other provisions of this Clause 20, any dispute that involves the validity, infringement or claim interpretation of a
Patent that is issued: (a) in the United States shall be subject to actions before the United States Patent and Trademark Office and/or submitted exclusively to the federal court located in the jurisdiction of the district where any of the
defendants resides; and (b) in any other country shall be brought before an appropriate regulatory or administrative body or court in that country, and the Parties hereby consent to the jurisdiction and venue of such courts and bodies. For the
sake of clarity, such Patent disputes shall not be subject to the provisions of Clause 20.2. Nothing in this Agreement shall be construed to prevent the Licensee from disputing or challenging the validity of a Third Party’s Patent. 

  
 28 

	21.	 Miscellaneous 

 

	21.1	 General assurances 

At any time after the date hereof each of the Parties shall, at the request and cost of the other Party, execute or procure the execution of
such documents and perform or procure the performance of such acts as the other Party may reasonably require for the purpose of giving to the other Party the full benefit of all the provisions of this Agreement, subject to any express restrictions
in this Agreement on the extent of either Party’s obligations under this Agreement. This includes in particular (without prejudice to the generality of the foregoing) entry into forms of licence or other instruments confirming such rights for
registration with appropriate Intellectual Property Offices (including in the form set out in Schedule 4), Regulatory Authorities and other authorities in the Territory. 
  

	21.2	 Unenforceability and severability 

If any of the provisions of this Agreement are held to be void or unenforceable, then such void or unenforceable provisions shall be replaced
by valid and enforceable provisions that will achieve as far as possible the economic business intentions of the Parties. However, the remainder of this Agreement will remain in full force and effect, provided that the material interests of the
Parties are not affected, i.e. the Parties would presumably have concluded this Agreement without the unenforceable provisions. 
  

	21.3	 Assignments 

Neither this Agreement nor any of the rights and obligations created herein is assignable or transferable by either Party without the prior
written consent of the other, such consent not to be unreasonably withheld or delayed. 
 Notwithstanding the preceding sentence, each Party
is entitled to assign this Agreement and any rights created herein to, subject to the assumption of the obligations herein by, any Affiliate of such Party or any purchaser of the whole or a substantial part of the business of such Party. For the
avoidance of doubt, the Parties agree that the Ascendis Platform Technology constitutes a substantial part of the business of Ascendis. 
  

	21.4	 Rights cumulative and other matters 

 

	 	(A)	 The rights, powers, privileges and remedies provided in this Agreement are cumulative and are not exclusive of
any rights, powers, privileges or remedies provided by law or otherwise. 

  

	 	(B)	 No failure to exercise nor any delay in exercising by any Party to this Agreement of any right, power,
privilege or remedy under this Agreement shall impair or operate as a waiver thereof in whole or in part. 

  
 29 

	 	(C)	 No single or partial exercise of any right, power privilege or remedy under this Agreement shall prevent any
further or other exercise thereof or the exercise of any other right, powers, privilege or remedy. 

  

	21.5	 Costs of preparation 

The Parties hereto shall pay their own respective legal costs incurred in the preparation of this Agreement. 

 

	21.6	 Entire Agreement and variation 

 

	 	(A)	 This Agreement, together with any documents referred to in it, constitutes the whole agreement between the
Parties relating to its subject matter and supersedes and extinguishes any prior drafts, agreements, undertakings, representations, warranties and arrangements of any nature, whether in writing or oral, relating to such subject matter. All
information related to the subject matter of this Agreement previously exchanged shall be protected under Clause 10 of this Agreement as if disclosed under this Agreement. 

 

	 	(B)	 Each Party acknowledges that it has not been induced to enter into this Agreement by any representation or
warranty other than those contained in this Agreement and, having negotiated and freely entered into this Agreement, agrees that it shall have no remedy in respect of any other such representation or warranty except in the case of fraud.

  

	 	(C)	 No variation of this Agreement shall be effective unless made in writing and signed by each of the Parties.

  

	21.7	 Notices and invoices 

 

	 	(A)	 Any notice (which term shall in this Clause 21.7 include any communication) required to be given under this
Agreement or in connection with the matters contemplated by it shall, except where otherwise specifically provided, be in writing in the English language. 

  

	 	(B)	 Any such notice shall be addressed as provided in Clause 21.7(C) and may be: 

 

	 	(1)	 personally delivered, in which case it shall be deemed to have been given upon delivery at the relevant address
if it is delivered not later than 17.00 hours on a Business Day, or, if it is delivered later than 17.00 hours on a Business Day or at any time on a day which is not a Business Day, at 08.00 hours on the next Business Day; 

 

	 	(2)	 sent by pre-paid registered airmail, or by air courier in which case it
shall be deemed to have been given seven (7) Business Days after the date of posting in the case of registered airmail or two (2) Business Days after delivery to the courier, in the case of air courier; 

 

	 	(3)	 sent by electronic mail, in which case it shall be deemed to have been given when sent from the electronic mail
exchange, provided that any notice sent by electronic mail after 17.00 hours on any Business Day or at any time on a day which is not a Business Day shall be deemed to have been given at 08.00 on the next Business Day. 

  
 30 

	 	(C)	 The addresses and other details of the Parties referred to in this Clause 21.7(C) are, subject to Clause
21.7(D): 

 Ascendis’ address: 

Ascendis Pharma Growth Disorders A/S 

Tuborg Boulevard 5 
 DK-2900 Hellerup 
 Denmark 

Email: [***] 
 Attention: [***]

 VISEN Pharmaceuticals’s address: 

VISEN Pharmaceuticals 
 P.O. Box
472 
 2nd Floor, Harbour Place 

103 South Church Street 
 George
Town, Grand Cayman KY1-1106 
 Cayman Islands 

Email: [***] 

Attention: [***] 
  

	 	(D)	 Either Party to this Agreement may notify the other Party of any change to the address or any of the other
details specified in Clause 21.7, provided that such notification shall only be effective on the date specified in such notice or five (5) Business Days after the notice is given, whichever is later. 

 

	 	(E)	 Invoices 

All invoices that are required or permitted under this Agreement shall be in writing and sent by Ascendis to the Licensee at the address
provided under Clause 21.7(C). 
  

	21.8	 Force Majeure 

Neither Party to this Agreement shall be deemed to be in breach of this Agreement or otherwise liable to the other as a result of any delay or
failure in the performance of its obligations under this Agreement if and to the extent that such delay or failure is caused by Force Majeure, and the time for performance of the relevant obligation(s) shall be extended accordingly. The Party
concerned shall promptly notify the other Party of the nature and effect of such event and both Parties shall, where the same is practicable, use Diligent Efforts to minimise such effect and to comply with the respective obligations herein contained
as nearly as may be in their original form, provided that if the Force Majeure event continues for a period of ninety (90) days or more following notification, the Party not affected by the event may terminate this Agreement by giving not less
than thirty (30) days prior notice to the other Party. 

  
 31 

	21.9	 Relationship of the Parties 

 

	 	(A)	 Nothing in this Agreement shall constitute, or be deemed to constitute, a partnership between the Parties nor,
except as expressly provided, shall it constitute, or be deemed to constitute, any Party the agent of any other Party for any purpose. 

  

	 	(B)	 Subject to any express provisions to the contrary in this Agreement, neither Party shall have any right or
authority to and shall not do any act, enter into any contract, make any representation, give any warranty, incur any liability, assume any obligation, whether express or implied, of any kind on behalf of the other Party or bind the other Party in
any way. 

  

	21.10	 Counterparts 

This Agreement may be executed in any number of counterparts, which shall together constitute one Agreement. Any Party may enter into this
Agreement by signing any such counterpart. 
  

	21.11	 Third Party rights 

No person who is not a party to this Agreement shall have any right to enforce any term of this Agreement. 

 

	21.12	 Governing law 

This Agreement shall be governed by and construed in accordance with the laws of the state of Delaware, USA, without reference to its conflict
of laws principles, and shall not be governed by the United Nations Convention of International Contracts on the Sale of Goods (the Vienna Convention). 

[Signature page follows] 

  
 32 

 AS WITNESS the Parties hereof have executed this Agreement the day and year first before written.

  

					
	Signed by	 	) /s/ Michael Wolff Jensen	 	
	for and on behalf of	 	) Michael Wolff Jensen, Chairman	 	
	ASCENDIS PHARMA	 	) /s/ Jan Mikkelsen	 	
	GROWTH DISORDERS A/S	 	) Jan Mikkelsen, CEO	 	
			
	Signed by	 	) /s/ Shan Fu	 	
	for and on behalf of	 	) Shan Fu	 	
	VISEN PHARMACEUTICALS	 	) Director	 	

  
 33 

 SCHEDULE 1 : ASCENDIS PATENTS 

[***] 

 SCHEDULE 2: ASCENDIS TECHNICAL INFORMATION 

 

	 	1.1	 [***] 

 SCHEDULE 3: EXCLUDED INDICATIONS 

[***] 

 SCHEDULE 4 : SHORT FORM PATENT LICENCE 

THIS AGREEMENT is made the [            ] day of
[            ] 
 BETWEEN: 

 

	(1)	 ASCENDIS PHARMA GROWTH DISORDERS A/S, (“Ascendis”), a company registered in
Denmark with its registered office at Tuborg Boulevard 5, DK-2900 Hellerup, Denmark; and 

  

	(2)	 VISEN PHARMACEUTICALS, a company registered under the laws of Cayman Islands with its registered
address at P.O. Box 472, 2nd Floor, Harbour Place, 103 South Church Street, George Town, Grand Cayman KY1-1106, Cayman Islands. 

Ascendis and the Licensee are each a “Party”, and together the “Parties”, to this agreement. 

Ascendis hereby grants to the Licensee an exclusive licence for exploitation of the patent(s) set out in the Appendix below worldwide for the treatment and/or
prevention of any disease, condition or disorder of the eye and adnexa, defined according to WHO ICD (but non-exclusive for Diabetic Retinopathy), subject to and terminable in accordance with the terms and
conditions of an agreement between the Parties hereto dated [    ]. 
 Appendix 

[insert details of relevant patents/patent applications] 

AS WITNESS the Parties have executed this agreement the day and year first above written. 

 

					
	 Signed by
	  	)	 	
	 for and on behalf of
	  	)	 	
	 ASCENDIS PHARMA
	  	)	 	
	 GROWTH DISORDERS A/S
	  	)	 	
			
	 Signed by
	  	)	 	
	 for and on behalf of
	  	)	 	
	 VISEN PHARMACEUTICALS
	  	)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00294-of-00352.parquet"}]]